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Introduction  
The Sickle cell diseases (SCD), a group of autosomal recessive disorders is caused by point 
mutation at the 6th position in β globulin chain of hemoglobin, substituting valine for glutamic 
acid resulting in formation of hemoglobin S (HbS). SCD can occur through homozygosity for the 
sickle (S) β-globin mutations or by compound heterozygosity of S β-globin mutations with other 
variant β globin gene mutations. Examples of this include, but are not limited to, SC Disease, 
Sickle-β thalassemia and SE disease.
 
The HbS has a tendency to polymerize which results in 
deformed red cells leading various clinical manifestations. (1) 
The sickle cell disease is clinically heterogeneous disease and this variability in manifestation 
ranges from being totally asymptomatic to severe crisis which can be fatal. The Sickle cell 
disease mostly follows a benign course in Indian patients as compared to African and American 
patients. (2) 
Hydroxyurea has been approved by US Food and Drug Administration (FDA) for treatment of 
sickle cell anemia.  However, there have been very few studies in literature regarding the role of 
hydroxyurea in Indian patients where the underlying disease course is milder than Western 
patients. There are a large number of patients under our follow up and many of whom are on 
Hydroxyurea treatment. Thus this study was under taken to retrospectively analyze records of 
sickle cell disease patients from 2005-2013 for their clinical presentation, demographic data, 
treatment details and their response rates to Hydroxyurea. 
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Review of Literature 
The relevant literature regarding sickle cell disease will be reviewed as follows 
I. Definition and classification 
II. Epidemiology 
III. Genetic Basis and Pathophysiology 
IV. Clinical Profile and Complications 
V. Phenotypic Heterogeneity and Genetic modifiers 
VI. Management of Sickle cell disease and Role of Hydroxyurea  
I. Definition and Classification: 
In 1910, James Herrick, for the first time recognized  a clinical entity with symptom complex of 
anemia, recurrent fever and bouts of bone pains associated with sickle shaped red blood cells 
which was subsequently named as Sickle cell anemia.(2) 
The term sickle cell disease is used for all different genotypes that cause characteristic clinical 
syndrome whereas sickle cell anemia is usually used to refer specifically to homozygous HbS 
disease (HbSS). The various genotypes that can be associated with SCD phenotype include 
HbS/Beta thalasemia, HbSC and other rarer genotypes like HbS/HbE , HbS/HbD etc.(3) 
II. Genetic basis and Pathophysiology 
Hemoglobin S (HbS) is formed as result of mutation in beta globulin gene in which 17th 
nucleotide is changed from thymine to adenine  which leads to substitution of valine instead of 
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glutamic acid at sixth amino acid in beta globulin chain. This mutation produces a hydrophobic 
motif in deoxygenated HbS. The SCD phenotype can occur in both homozygous state or in 
compound heterozygous states in which HbS is combined with other mutation on second beta 
globulin gene such as beta thalasemia, HbC, HbD , HbE etc.(3) 
In 1949, Linus Pauling and Colleauges discovered sickle hemoglobin (HbS) due to its 
differential electrophoretic mobility on gel electrophoresis and this was first demonstration of an 
abnormal protein linked to genetic disorder. Thus the term "molecular disease" was coined and 
sickle cell disease was the first example. (4) 
 In ensuing decades, detailed pathophysiology of SCD was described based on abnormal 
polymerization of deoxygenated HbS. More recent data has indicated the role of endothelial 
activation with increased adhesion, vasoconstriction and coagulation activation in pathogenesis 
of SCD. 
POLYMERIZATION OF HbS 
The concentration of Hb within RBCs is very high (32-34g/dl) and this requires hemoglobin 
molecule to be highly soluble. After deoxygenation of HbS, the replacement of hydrophilic 
glutamic acid with hydrophobic valine results in interaction with another deoxygenated HbS 
molecule, triggering an aggregation which leads formation of large polymers. The repeated 
cycles of oxygenation and deoxygenation of RBCs produce repeated sickling and unsickling, 
leading to RBC damage and increased rate of red cell breakdown as well as short-lived sub-
populations of very high density irreversibly sickled RBCs. This polymerization of deoxygenated 
HbS is the primary event in the pathogenesis of sickle cell disease, which results in a distortion 
of the shape of the red cell with marked decrease in its deformability. These rigid red cells are 
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responsible for the vaso-occlusive phenomenon which is considered the hallmark of the disease. 
(5)  
The polymerization of HbS is a dynamic event and kinetic features of polymer formation are 
determinants of the shape and morphology of red cells. If deoxygenation is rapid, multiple 
independent polymerization events occur, that result in a granular or cobblestone texture which 
does not alter the cell’s disk-like shape. In contrast, when sickle red cells are slowly or partially 
deoxygenated, there is formation of single nucleus of aggregated molecules of deoxygenated 
hemoglobin S. This nucleation is leads to growth and alignment of fibers, which transforms the 
cell into a classic sickle shape. This distortion of the shape of the red cell by projections of 
aligned hemoglobin S fibers has an important role in disturbing the structure and function of the 
membrane in sickle red cells, enhanced in part by oxidant stress (6,7). 
The rate and amount of polymer formation in a circulating sickle red cell depend primarily on 
three factors: the degree of deoxygenation, the hemoglobin concentration in RBC, and the 
presence or absence of hemoglobin F. The lag period required for the formation of polymer is 
designated as the delay time which is inversely proportional to the HbS concentration in the red 
cell. As the range of transit times in the microcirculation is usually short as compared to the 
range of delay times for sickle red cells, polymers are not formed in most of the red cells (over 
80 percent) during their flow through the arterioles and capillaries.(8) 
The formation of polymer fibers in sickled RBCs triggers cascade of other cellular abnormalities 
involved in overall pathophysiological mechanisms. Dysregulation of cation homeostasis results 
from the activation of various ion channels including the K-Cl co-transport system and the Ca-
dependent K-channel (Gardos channel) in particular, which leads to a loss of potassium resulting 
 
 
5 
 
cellular dehydration. Because of cellular dehydration, the intracellular Hb concentration 
increases, favoring deoxy-HbS polymerization. The Hb in sickled red cells becomes denatured 
and hemichromes are concentrated at the internal side of the membrane along with proteins of 
the cytoskeleton, particularly protein band 3. This process also involves the loss of heme and the 
release of Fe3+ which promotes the formation of an oxidizing microenvironment. This leads to 
disruption of normal asymmetry of cell membrane with exposure of phosphatidylserine at cell 
surface. Due to exposure of Band 3 protein, Anti-band 3 IgGs accumulates on the protein band 3 
aggregates, leading to erythrophagocytosis by macrophages. Finally, all these membrane changes 
lead to the production of micro particles. (9, 10) 
As RBCs are the predominant cell type in blood, so their characteristics largely determine the 
rheologic and hemodynamic behavior of blood. The interactions of the RBC membrane skeleton 
and membrane proteins with the lipid bilayer provide the flexibility for RBC to deform under 
shear stress in circulation and to regain its shape as a biconcave disk. In SCD, formation of 
hemoglobin polymers in the sickled RBC affects the RBC’s ability to maintain its normal 
morphology especially during shear stress. The recurrent episodes of sickling form stiff and 
fragile RBC, which in turn leads to vasoocclusion and hemolytic anemia respectively. (11) 
However these mechanisms do not explain the events that triggers VOCs. As explained earlier, 
during basal conditions, the delay time which is necessary for the polymerization of deoxy HbS 
is usually longer than the time required for of passage of RBCs in microcirculation. Recent data 
provide additional evidence on various mechanisms including slowing down the blood flow in 
the microcirculation, are likely to trigger VOCs. (10) 
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Role of Vascular Endothelium  
The polymerization of deoxy HbS which subsequently leads to stiffening and fragility of sickled 
red cells explains the pathogenesis of vasoocclusive crises and hemolytic anemia noticed in 
SCD. However, it does not to explain the triggering of vasoocclusive crisis as under basal 
condition, the time required for sickling (referred as delay time) is usually more than time of 
passage of RBCs in microcirculation. Accordingly, various studies were carried out to study the 
interaction between SS red cells and vascular endothelium and the factors that can lead to slowed 
passage of RBCs in microcirculation which can trigger polymerization within RBCs and 
ultimately precipitate VOC. 
During 1980s,  the team of R.P. Hebbel  showed that there is an increased adhesion of the sickled 
RBCs to the endothelium that delays their passage through microcirculation.. The study revealed 
that the main cells responsible for this abnormal adhesion are a population of young RBCs, 
called as “stress reticulocytes”. These stress reticulocytes, come out prematurely from the bone 
marrow due to anemic stress and express on their surface certain adhesion proteins that are 
normally required for their homing in the marrow.(12)  
The first molecules identified responsible for this abnormal interactions on RBCs were the α4β1 
integrin ,  very late antigen-4 (VLA-4) which directly binds both to fibronectin and the vascular 
cell adhesion molecule-1 (VCAM-1)  which is expressed on the endothelial surface, especially 
after activation. In addition,  CD36 which is expressed both sickled red cells and endothelium,  
interact with each other through a molecular bridge formed by a molecule of thrombospondin 
(TSP) secreted by activated platelets. In addition, numerous other receptor/ligand couples have 
been subsequently identified on the red blood cells, on one side, and on the endothelial cells on 
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the other, and involvement of various plasma proteins in addition to TSP, with description of 
intricate network of probably co-operative as well as redundant interactions. The situation varies 
differs to the vascular territories, e.g, VCAM-1 is specific for the endothelial cells of the 
microcirculation whereas von Willebrand factor mediates abnormal cell-cell adhesions in large 
vessels. (13) 
The ongoing endothelial activation  is evident as  number of circulating endothelial cells(ECs) 
showing increased expression of  E-Selectin, P-Selectin, ICAM-1 and VCAM-1 are present in 
sickle cell patients. The role P-Selectin has been especially studied in detail in murine models 
and its pivotal role in pathogenesis of vasocclusive crisis has been explained in knockout mice 
models.(14) 
Sickle cell Vasculopathy 
For decades, vaso-occlusion by rigid sickled red cells leading to tissue infarction was considered 
the only cause of organ dysfunction in patients with SCD. In 1991,  Ballas et al, suggested two 
distinct sub phenotypes of clinical complications in SCD , one with recurrent painful crises and  
the other with recurrent ulcerations. (15).  Furthermore, studies by  Duits and Schnog expanded 
concepts of vascular dysfunction and   epidemiologic studies from Serjeant and colleagues in 
2004 further  refined  Balla's concept of SCD sub phenotypes.(the leg ulcer versus painful 
crisis).(16) 
In the last decade, Gladwin and his colleagues outlined the importance of haemolysis in 
pathophysiology of SCD. In his study, Gladwin and his colleagues demonstrated due to 
intravascular hemolysis, hemoglobin and arginase are released from the red cells into plasma, 
where they scavenge nitric oxide (NO) as well as its precursor L-arginine. This reduces NO 
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bioavailability, especially in those patients with the high rate of hemolysis. The depletion of No 
is associated with vasoconstriction as well as endothelial dysfunction. The chronic NO depletion 
has also been implicated in development of vascular proliferation, pulmonary hypertension and 
activation of endothealial cells and platelets as well as in release of potent vasoconstrictor 
Endothelin.(16) 
Subsequently, Kato and Gladwin showed that subgroup of SCD patients have high intravascular 
hemolysis, with decreased nitric oxide bioavailability, pulmonary hypertension, priapism and leg 
ulceration. Combining their own data with Steinberg and publications by others, a vasculopathy 
subphenotype was formulated by them comprising pulmonary hypertension, priapism, leg 
ulceration and preliminarily stroke, versus a viscosity-vaso-occlusive subphenotype involving 
vasoocclusive pain crisis, the acute chest syndrome and osteonecrosis.(17) 
 The role of  Polymorphonuclear neutrophils (PMN) in the precipitation of VOC and has also 
been described in last decade.H yperleukocytosis is very common finding  in SCD patients, and a 
high PMN count is a has been shown to  negatively impact overall survival in SCD. The 
presence of adherent leukocytes in small post-capillary veinules suggests that leukocytes, 
because of their cell volume, are major participants in slowing down the microcirculation that 
initiates VOCs. In addition, invitro studies have shown that SS-RBCs can interact with 
leukocytes and particularly with PMNs.(18) 
Coagulation Activation 
The SCD is considered as hypercoagulable state due to multiple factors. There is chronic 
depletion of NO, which leads to activation of platelets as well as release of many procoagulant 
factors. As phosphatidylserine is abnormally exposed at the surface of sickled RBC and tissue 
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factor is expressed by activated circulating ECs and monocytes, these together participate to a 
borderline activation of the coagulation system. This leads to generation of thrombin, albeit at 
minimal level, which in turn exacerabrates the underlying ischemia-reperfusion injury associated 
with vasoocclusive crises. 
In summary pathogenesis of sickle cell disease is driven by the principles of hemoglobin S 
polymerization within red RBCs, modulated by factors like inflammation and cellular adhesive 
events in the microcirculation which leading to ischemia and reperfusion events. This is 
amplified by intravascular hemolysis with deprivation of NO, activation of coagulation, 
increasing the expression of critical adhesion molecules on RBCs and endothelium along with 
leukocytes, and platelets that leads to sickle cell vasculopathy resulting in chronic organ 
dysfunction in patients of SCD. 
 
III. Epidemiology: 
SCD is one of the most common inherited blood disorder affecting human beings. It is believed 
that sickle Hb originated in Africa and population migration is responsible for wide spread 
dissemination of the gene. In addition, India is considered the place of origin. It is estimated that 
250,000 children are born annually with SCD worldwide and is among the most important 
epidemiological genetic diseases in the world.(19) 
In Africa, where disease has originated, the carrier frequency is about 10-30% in some regions. It 
is estimated that 200,000 new cases of SCD occur each year in Africa and more 70% of SCD 
patients live in Africa and is identified as a problem of major public-health significance.(Q) 
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In US, SCD is the most common inherited blood disorder with about 70,000 people living with 
SCD. It is more common in African-American and occurs 1 in every 500. The yearly estimate of 
affected births in North America is 2600. (2) 
In UK, SCD affects 1 in 1300 live births, and about 12,000 individuals are living with SCD, 
making SCD the most common and fastest-growing genetic disorder in the UK. (2,20) 
 In 1952, Lehman and Cutbush first time detected Sickle gene among the tribal population of 
Nilgiri Hills and almost at same time Dunlop and Mazumder   detected five cases of sickle 
Cell trait and three presumptive cases of sickle cell anemia among labourers in Assam, 
originating from  tribal populations of Bihar and Orissa . Subsequent studies have revealed a 
high prevalence of sickle cell disease in India. The highest prevalence has been recorded in the 
Orissa (1-44.4%), followed by Madhya Pradesh (1-40.0%; including Chhattisgarh), Tamil Nadu 
(1-40.0%), Andhra Pradesh (1-35.7%), Assam (1-35.5%), Maharashtra (0.8-35.0%), Gujarat (1-
31.4%),Kerala (1-30.0%), Uttar Pradesh (1.5-18.5%), Karnataka (1-8.0%), Rajasthan (1-5.7%), 
West Bengal (1-1.7%), and Bihar (0.8%; including Jharkhand).(21) 
Although the exact incidence and prevalence of SCD is not known in India, due to lack of 
population based registry in majority of places, SCD still represents a significant public health 
problem in India. With a population of over 1.2 billion individuals, it is estimated that India is 
home to over 50% of world’s SCD patients and the annual number of newborns in India with 
SCA was estimated at 44,000 .(22) 
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IV. Clinical Profile and Complications 
There is marked heterogeneity in clinical presentation in patients with sickle cell disease ranging 
from totally asymptomatic to life threatening condition like acute chest syndrome. More 
common presentations include musculoskeletal pain due to occlusive crisis and increased 
weakness due to symptomatic anemia. The rarer presentations include avascular necrosis of head 
of femur, priapism, non-healing ulcer and acute chest syndrome. The physical examination is 
may reveals moderate splenomegaly usually in cases of compound heterozygous HbS/Beta 
thalassemia cases, along with mild pallor. The veno occlusion and hemolysis, which are the hall 
mark of SCD lead to major clinical manifestation and various complications and are described 
below. 
1.Acute painful episodes (Veno occlusive Crisis): 
Acute pain is the first symptom of the disease in 25% of patients and recurrent episodes of acute 
pain, also known as veno-occlusive episodes or veno occlusive crisis (VOC) is the most common 
manifestation of the disease. VOC is defined as the occurrence of pain in the extremities, back, 
chest, abdomen, or head that lasts two or more hours and is considered hall mark of SCD.(23) 
The pain in hands and feet (known as dactylitis ) is the most common symptom in children who 
present before two years of age and occur in 50% of children with SCD. The frequency of 
painful episodes usually peaks between 19-39 years and in patients. In a study by Platt OS et al, 
it was shown that patients aged above 20 years, higher frequency of acute painful episodes was 
associated with higher mortality.(24)  
There is considerable variability in frequency and severity of painful episodes. Some patients 
may have six episodes annually while others may have fewer than three episodes and still many 
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patients do not have painful episodes at all. In a study by Cooperative Study of Sickle Cell 
Disease , the mean number of pain episodes/ year was 0.8 in SCA, 1.0 in sickle cell-beta (0) 
thalassemia, and 0.4  sickle cell-beta (+) thalassemia. Among the patients with SCA, 40 percent 
had no painful episodes, while 1 percent had 3 to 10 episodes/ year.(24,25). 
The  acute painful episodes usually  affect long bones and joints, and  the low back is the most 
frequently reported site of pain .In children, pain in hand and feet is usually the presenting 
manifestation. Other parts of the body which may be involved include the scalp, face, jaw, 
abdomen, and pelvis. The occurrence of three or more of acute painful episodes in year indicates 
that the patient has severe SCD. The severe abdominal pain can present as acute abdomen. (25). 
Most studies have studied the pain frequency based on hospital emergency department visits. 
However, Smith WR et al studied the pain frequency as reported by patients on daily basis to 
assess the frequency of self-reported pain.  They concluded that pain was reported in 55 percent 
of analyzed patient days and 29 percent of patients had pain almost daily. In this study, a painful 
episode without using hospital care was the" rule rather than the exception" and concluded that 
previously reported frequency of painful crises is an underestimate.(26) 
The various factors that may precipitate pain episodes include dehydration, weather conditions, 
stress, infection, menses and rarely obstructive sleep apnea. However, in most cases, no 
precipitating factor may be identified. In about half of the pain episodes, clinical signs such as 
fever, swelling, tenderness, tachypnea, nausea, and vomiting is present.(27) 
There are no diagnostic test to diagnose  a vaso-occlusive episode and diagnosis is usually made 
on the basis of clinical features .The peripheral blood smear may reveals  5 to 50 percent of the 
red cells are irreversibly sickled RBCs . The most useful laboratory indicators of acute episode of 
 
 
13 
 
VOC are changes in density distribution of sickled RBC subpopulations and the rheologic 
properties of the blood, but tests may not be readily available. The pain episode is also associated 
with changes in levels of acute phase reactants (eg, C-reactive protein, fibrinogen) , serum lactate 
dehydrogenase, interleukin-1, tumor necrosis factor, and serum viscosity.(28) 
 In addition to acute painful episodes, many patients in SCD experience chronic low level pain, 
mainly in bones and joints, with intermittent exacerbation as acute episodes. 
2. Anemia  
Sickle cells are mechanically weak and are prone to hemolysis leading to anemia. However, as it 
is chronic, it is usually well tolerated. In a study by Embury SH et al, the mean hemoglobin in 
patients with SCD was 7.9g/dl. The anemia is usually more severe in homozygous state while 
variants of SCD patients are usually less anemic. The other factors which may worsen the the 
underlying chronic anemia is folate deficiency if not appropriately replaced.(29) 
There are some complications of SCD which can lead to rapid drop in hemoglobin with resultant 
acute severe anemia. These include splenic sequestration, aplastic crisis and hyper hemolytic 
crisis and will be discussed separately. 
3. Neurological complications 
The neurological complications are one of the major complications in SCD. In patients of SCD, 
about 24% experience and overt clinical event like stroke by 45 years of age and in children, 
about 25% have silent ischemic changes that may impair neurocognitive function. In both 
children and adults, cerebrovascular events are one of the leading causes of mortality.(30,31) 
The CNS complications in SCD include cerebral infarct, intracranial hemorrhage as well as 
cognitive and behavioral abnormalities.  In a study by Cooperative Study of Sickle Cell Disease 
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(CSSCD), the incidence of CVA in homozygous sickle cell anemia was 0.61 per 100 patent 
years while it was0.08-0.09 in sickle beta thalassemia patients.(30) 
The cerebral infarcts are more common in children with SCD as compared to adults. In a study 
by CSSCD, incidence of cerebral infarct per 100 patient years was 0.7 between ages 2-5 years 
while it was 0.04 between ages 20-29 years.  The recurrent strokes occur in about two-thirds of 
SCD patient within two years of first stroke. The recurrent strokes are more common in children 
as compared to adults and are associated with more neurological deficits. The risk factors for 
cerebral ischemia includes low steady state hemoglobin, previous history of transient ischemic 
attack, history of acute chest syndrome and high systolic blood pressure.(30). 
The role of Trans cranial Doppler (TCD) in predicting the risk for stroke in children has been 
well established. It measures the mean velocity of blood flow in large intracranial arteries in 
circle of Willis which is inversely proportional to the diameter of the vessel. In children, a mean 
TCD velocity >200 cm/sec in the middle cerebral artery or internal carotid artery are highly 
associated with increased risk of stroke. In a study by Adam R et al, 283 TCD were performed in 
190 children and young adults with SCD (age at entry was 3 to 18 years). Of 190 patients, 23 
patients (12 percent) had an abnormal TCD (based upon highest blood flow velocity in the 
middle cerebral artery), and total of seven patients developed a cerebral infarction after an 
average follow-up of 29 months. Among seven strokes, six occurred from the 23 patients with 
abnormal ultrasound results. (32,33) 
In addition to infarcts, one third of SCD patients have intracranial hemorrhages which can 
manifest as intracerebral, intraventricular or subarachnoid hemorrhage. In contrast to cerebral 
infarction, which is more common in children, the peak incidence of intracranial hemorrhage is 
between 20-29years. About 3% of patients with SCD will have an ICH by 20 years of age, of 
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which 25 to 50 percent will die within two weeks of the event. The subarachnoid hemorrhage is 
the most common site and is result of rupture of arterial aneurysm.  Multiple aneurysms are 
present in about 45% of SCD patients which are thought to result due to high flow conditions in 
cerebral circulation. The risk factors for an ICH in SCD patients include low steady state level of 
hemoglobin and high leucocyte count. (30,34) 
In addition to overt clinical events like stroke, subtle neurological dysfunction is being 
increasingly recognized in patients of SCD. In a study by Vichinsky EP, neurocognitive 
measurements were done in neurologically asymptomatic SCD patients. In this study, as 
compared to healthy age matched controls, SCD patients had poorer cognitive performance.(35) 
     Seizure disorder is two to three times more common in SCD patients than in non-sickle 
populations and is associated with increased mortality. In a study by Ali SB et al, all records of 
the 543 persons in the Jamaica sickle cell cohort were analyzed and it was found that five-year 
cumulative incidence of febrile convulsions was 2.2 percent and the incidence rate of epilepsy 
was 100 per 100,000 person-years. The risk factors for epilepsy included male gender and 
history of dactylitis in childhood.(36) 
3.Pulmonary Complications and Acute chest Syndrome 
The slow flow and low oxygen tension in pulmonary arterial circulation forms an ideal 
environment for HbS polymerization and subsequent vasoocclusion. This leads to both acute and 
chronic pulmonary complications in SCD patients and is leading cause of mortality in SCD 
patients. The evaluation of SCD patients reveals variety of chronic complications like restrictive 
and obstructive lung disease, asthma or recurrent wheezing, pulmonary hypertension and 
pulmonary fibrosis.(37,38) 
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The baseline oxygen saturation in asymptomatic SCD patients has been found to be low as 
compared to healthy controls when measured by pulse oximetry. In a study by Uong EC et al, 
studied 130 patients of SCD and found that mean day time oxygen saturation was below normal 
levels.(39). 
Pulmonary hypertension (PH) is increasingly being recognized as one of the major complications 
of SCD patients and is associated with increased mortality. The major risk factor for pulmonary 
hypertension is the severity of hemolysis in SCD patients. The prevalence of pulmonary 
hypertension is 30-40 percent in homozygous sickle cell anemia in studies where SCD patients 
were screened by echocardiography. However, using right heart catheterization, the prevalence 
of pulmonary hypertension was found to be 6-10 percent.(40,41) 
The patient usually presents with exertional dyspnea and excessive fatigue. The other symptoms 
which may be present include pedal edema and signs of right heart failure due to right heart 
failure in advanced cases. The diagnosis can be confirmed by right heart catheterization which 
documents a mean resting pulmonary arterial pressure of >25mmHg. However the hemodynamic 
features may vary across the SCD patients with some having predominantly pre capillary PH 
while others as post capillary PH and still others may have combination of both. 
The venous thromboembolism and pulmonary arterial thrombosis are common in patients of 
sickle cell disease. In a cross sectional study by Naik RP et al, among 404 patients, 25% had 
history of venous thromboembolism of which 19% were non-catheter related and the median age 
at diagnosis was 29.9 years.(42) In a study by Stein PD et al, data from National Hospital 
Discharge Survey was analyzed and it was observed that prevalence of pulmonary embolism in 
SCD patients  was 0.44% as compared to 0.12% in patients without SCD. In addition, in patients 
with SCD, the pulmonary embolism was associated with longer hospital stay, greater severity of 
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illness as well increased mortality as compared to non-SCD patients with pulmonary 
embolism.(43) 
Pulmonary fibrosis may is rarely seen patients with SCD and may be the result of recurrent 
episodes of acute chest syndrome with pulmonary infarction.(41) 
Acute Chest Syndrome (ACS) 
Acute chest syndrome, defined as the new appearance on an infiltrate on chest x-ray along with 
fever and/or pulmonary symptoms is the most common acute pulmonary complication in patients 
with sickle cell disease, occurring in 30-50% of patients. It is more common in children with an 
incidence rate of 25.3 per 100 patient years as compared to adults with an incidence rate of 8.78 
per 100 patient years. It is the leading cause of mortality in adult patients with SCD with a death 
rate of 1.8% in children and 4.3% in adults. It is more common in homozygous sickle cell 
disease as compared to compound HbS/beta thalassemia with incidence rates of 3.27 and 1.95 
per 100 patient years respectively. In patients of SCD, ACS is the second most common cause of 
hospitalization.(38) 
The clinical features of ACS included fever, chest pain, pain in extremities and dyspnea, and the 
symptoms were more prevalent in adults as compared to children. In addition, the adult patients 
with SCD have prolonged hospital stay, more severe illness and increased risk of death as 
compared with children with SCD during an episode of ACS. ACS developed in about half of 
the SCD patient during the hospitalization for other complication of SCD most commonly with 
acute painful episode.(44) 
The etiology of ACS is multifactorial and includes pulmonary infarction, infection (which can be 
due to viruses, Chlamydia or mycoplasma) and fat embolism. In a study by Vichensky EP, 671 
episodes of ACS were analyzed and the definitive etiology could be established in 38% of ACS 
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episodes after extensive evaluation. It included infections (29 percent of all episodes), pulmonary 
infarction (16 percent) and fat embolism (9 percent). In 46% of episodes either data was 
incomplete or no diagnosis was established.(44) The risk factors for ACS include VOC , 
postoperative status, history of asthma and chronic hypoxemia.(38) 
The diagnosis of ACS is made clinically on the basis of new pulmonary infiltrate which involves 
at least one complete lung segment detected on chest x-ray along with fever and/or pulmonary 
symptoms. The investigations include chest x-ray, electrocardiogram, and complete blood count 
along with blood and sputum cultures. In addition, CT scan of chest and bronchoscopy with 
bronchioalveolar lavage may be done in certain situations. 
The therapy of ACS includes oxygen, analgesia for pain control, antibiotics and blood 
transfusion. In addition exchange transfusion may be required in some cases. In view of 
bronchial hyper reactivity, broncho dilators are often used.(45) 
 
4. Osteonecrosis. 
The avascular necrosis (AVN) also known as osteonecrosis is well described complication of 
SCD. The commonly involved sites include head of femoral and head of hemurus. The lesser 
common sites of involvement include condyles of mandible, elbow and temporomandibular 
joint. 
The femoral head is the most common site of involvement. In a study of 2590 SCD patients in 
the Cooperative Study of SCD with a mean follow up of 5.6 years, 10% patients had  AVN at 
entry. The overall incidence estimated was 2-4.5 per 100 patient years. The presence of alpha 
thalassemia mutation was associated with higher incidence of AVN while increased levels of 
HbF were protective.(46) 
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The AVN in femoral head presents with pain in the hips and progresses to decreased mobility, 
abnormal gait and limb length discrepancy. It is found in all ages including children as young as 
five years.  In a study by Hernigou P et al, 95 affected hips in 52 SCD patients,  who were 
diagnosed with AVN of the femoral heads in childhood, were studied after an average duration 
of 19 years after the onset of AVN, pain was present in  80 percent of the affected hips  and 
showed permanent damage ,the pain was first noticed at an mean age of 12 years (range 7 to 15 
years), and about 16%(15 of the 95) of affected hips required a surgical procedure at a mean of 
30 years (range 18 to 32 years) after onset of AVN. (47)  
The diagnosis is made by radiological imaging with an MRI. Although AVN is usually 
associated with pain, about 50% of SCD patients had AVN on imaging in surveillance study out 
of which 21% of patients became symptomatic subsequently.(46). 
The treatment of femoral AVN includes conservative management with pain relief, walking aids 
and physical therapy to strengthen the hip muscles and maintain range of motion at the hip joint, 
and surgical interventions like core decompression and arthroplasty. 
5.Infection 
Infections are major contributors of morbidity and mortality in patients of sickle cell disease. As 
SCD patients have hyposplenism due to sickling of red cells within splenic circulation, SCD 
patients are susceptible to overwhelming infection by various pathogens especially by capsulated 
organisms like Streptococcus pneumoniae and Haemophilus influenzae. The viral infections like 
Parvo viruses and H1N1 can lead severe illness in SCD patients. In addition, malaria is known 
cause of increased mortality in children with SCD.  Infections also provoke a cascade of SCD-
specific pathophysiological processes which can lead various complications like VOC and acute 
chest syndrome. Historically, infection has been a major cause of mortality in SCD, especially in 
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children, and was implicated in 20-50% of deaths in various prospective cohort studies over last 
20 years. (48,49). 
The Streptococci pneumoniae is most common cause of bacteremia in children with SCD. Before 
the prophylactic penicillin and pneumococcal vaccination were regularly used in children with 
SCD, bacteremia due to S. pneumoniae in infants with SCD was 4-10 episodes per 100 patient 
years . In addition, pneumococcal bacteremia is associated with a high risk of meningitis. 
Although the introduction of the pneumococcal conjugate vaccine has led to significant reduction 
of above 90 percent in the incidence of pneumococcal infection in children below the age of five 
years, the infection with pneumococcal serotypes  that are not included in these vaccines, and 
infection in those who are not vaccinated has continues to occur.(50) 
The second most common organism for bacteremia in children with SCD is Haemophilus 
influenzae type b and is responsible for 10- 25 percent of episodes. It is more common in older 
children and usually less fulminant as compared pneumococcal bacteremia. The incidence of 
invasive H. influenzae type b infection has markedly declined after the introduction of the H. 
influenzae type b vaccination.(49,52) 
The bacteremic episodes can lead to meningitis, pneumonia or osteomyelitis. The meningitis is 
especially common in young children and infants with SCD having S.pneumonea infection. 
Historically, as much as 50% of patients with bacteremia can develop meningitis, emphasizing 
the need for rapid antibiotic administration. (49) 
The incidence of bacterial pneumonia in patients with SCD is high and commonly involved 
organisms include mycoplasma, Chylmadia and Legionella while S. pneumoniae and H. 
influenza type b are uncommon. In addition, respiratory viruses can also cause pulmonary 
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infection. Patients usually present with   dyspnea, cough, fever, chest pain and tachypnea. 
Pulmonary infection can lead to development of acute chest syndrome.(52) 
The osteomyelitis and septic arthritis are well recognized complications in patients with SCD. 
The most common organism involved in osteomyelitis is salmonella while staph aureus is more 
commonly involved in septic arthritis. The clinical features include fever, local warmth and 
tenderness which may be difficult to differentiate from VOC. However, infectious episodes are 
usually more prolonged and pain is usually localized to a single site. It may be difficult to 
differentiate the osteomyelitis from VOC as imaging features in both are similar. In such cases 
biopsy of the lesion is the gold standard for diagnosis.(53) 
6. Splenic Sequestration 
Acute splenic sequestration is one of the life threatening complications in SCD patients which 
occur when vaso-occlusion occurs within the splenic circulation that prevents blood from leaving 
the spleen. This leads to pooling of blood in the spleen with acute fall in hemoglobin. It is more 
common in children with an incidence of 30 percent and is the initial symptom in about 20 
percent of patients. It is associated with 10- 15% mortality and is recurrent is 50% 0f cases. (54).  
The clinical features in splenic sequestration include precipitous fall in hemoglobin 
concentration with reticulocytosis, tender splenomegaly, fever, leukocytosis and 
thrombocytopenia. It leads to decrease in effective circulating blood volume, which can lead to 
hemodynamic instability and shock. In rare cases splenic rupture and death may occur. 
The treatment includes the blood transfusion and supportive care with pain relief, intravenous 
fluids and oxygen supplementation. In recurrent cases, splenectomy can be done, however, the 
frequency of VOC post splenectomy has been found to increase.(54,55)  
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7.Aplastic Crisis 
The infection with Parvo virus B19 causes a serious complication in patients of SCD termed aas 
aplastic crisis. It is characterized by transient arrest of erythropoesis leading to abrupt fall in 
hemoglobin with decreased reticulocyte count. In a study by Sergeant BE, 280 patients of SCD 
were studied; aplastic crisis occurred in 118 of 177 parvo virus B19-infected patients. About 
70% of patients had seroconvert by 20 years making parvovirus an uncommon cause of aplastic 
crisis in SCD after this age.(56). 
The management includes transfusion therapy to maintain normal hemoglobin concentration. It 
is usually transient phenomenon and resolves in 10-14 days. 
8. Priapism 
Priapism defined as penile erection in the absence of sexual activity or desire lasting more than 
two to four hours, is a well-recognized complication in SCD patients. It requires prompt 
recognition and treatment as recurrent episodes can lead to erectile dysfunction. The prevalence 
among boys and men with SCD ranges from 6 to 45 percent. The episodes of priapism can occur 
at any age, but is usually a more significant clinical problem after puberty. The mean age of 
onset is 12 - 15 years; with 75- 90% patients report their first episode prior to 20 years of age. 
(57) 
The patients with  can present with either  as  prolonged erection if it lasts for more > 3 hours or 
as stuttering episodes if it lasts for a few minutes but < 3 hours and resolves spontaneously or 
combination of both.(58) 
Although most episodes may resolve spontaneously, prolonged episodes need urgent medical 
attention with aspiration and irrigation of corpus cavernosum.(57,58) 
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9. Hepatobiliary Complications 
The liver is affected by a variety of SCD complication both directly as well as due to treatment 
of SCD. The various manifestations include acute hepatic sequestration crisis, benign cholestasis 
and sickle cell hepatopathy. The complications due to treatment of SCD include liver 
involvement due to transfusional iron overload, viral infections like Hepatitis B and heaptitis C 
due to transfusion related transmission. (59) 
Cholilithiasis is common in patients with SCD as chronic hemolysis leads to formation of 
pigment stones and is found in about 70 percent of patients. Choliltiasis can be asymptomatic or 
can present with acute cholecystitis, chronic cholecystitis or with choledocholithiasis. In a study 
by Adam S eta al, 509 adult patients with SCD were studied; cholecystectomy was done in 48% 
of patients between 18-47 years of age and in 69% of patients aged above 47 years. (59, 60)  
10.Growth and Development 
In children and adolescents, SCD is associated with delayed sexual maturation, growth 
retardation and being under weight. In a study by Rhodes et al, 33 SCD adolescent patients along 
with age matched controls were studied for growth parameters. They demonstrated that growth is 
delayed during puberty in the adolescent patients with SCD and this delay is independently 
associated with decreased hemoglobin concentration and increased total energy expenditure. The 
normal height is often attained by adulthood but weight usually remains lower than that of 
controls.  Both neurodevelopment and skeletal maturation are usually delayed.(61). 
In Jamaican Cohort Study by Singhal A et al, extreme growth retardation which was defined as 
absence of both the adolescent growth spurt as well as  prepubertal sexual development (Tanner 
stage 1 or 2) at  the age 16, was found  in 8 of 52 boys (15%) with SCD.(62) 
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11.others 
The SCD is a multisystem disease and any system can be affected by the disease process. In 
addition, SCD is known for considerable phenotypic heterogeneity in presentation. The other 
common complications which can occur in SCD patients include leg ulcers, retinopathy and 
nephropathy. 
Leg ulcers are more common in homozygous sickle cell anemia as compared to compound 
heterozygous states like sickle beta thalassemia and occur in about 10 per 100 patient years of 
SCD. In a study of 225 SCD patients from the Jamaican Cohort Study,  53 patients  (24 percent) 
had chronic leg ulcers and median age of first ulceration was about 17 years (range: 13 to 24) . 
The mode of onset was traumatic in 60% while it occurred spontaneously 28%. The risk factors 
detected were venous incompetence, increased levels of LDH and low socioeconomic status. The 
medial and lateral maleoli are most common site of involvement.(63) 
The ocular manifestation of SCD is one of important long term complications of SCD that have 
emerged because of the increase in life expectancy of SCD patients. SCD can affect any ocular 
structure but retina is most commonly involved and leads to proliferative retinopathy. It is more 
common in HbSC disease as compared to homozygous sickle cell anemia. Although spontaneous 
regression of retinopathy is known, loss of vision can occur in untreated cases. (64) 
  The kidney involvement occurs in 30-50% of adult patients with SCD and leads to renal failure 
in 18% of patients. It can manifest as asymptomatic albuminuria or patient may present with 
enuresis due to hyposthenuria, hematuria, and proteinuria with hypertension or with renal colic 
due to papillary infarction. The rarer presentation include nephrotic syndrome and nephrogenic 
diabetes insipidus.(65) 
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V. Phenotypic Heterogeneity: 
The clinical features of SCD are exceptionally heterogeneous. Clinical heterogeneity is present 
among the different genotypes of sickle cell disease (eg, SCA, HbSC disease, HbS-beta 
thalassemia) as well as in homozygous HbS. Although identical beta globulin gene mutation is 
present in all patients, the clinical course of patients with homozygous sickle cell anemia is 
highly variable. This suggests that product of other genes known as epistatic genes along with 
environmental factors are likely to determine the specific phenotype of SCA. (66) 
 The various modifiers of clinical expression are described below: 
1.Fetal Hemoglobin (HbF): 
Fetal hemoglobin (HbF) is the most thoroughly studied as well as most powerful genetic 
modulator of sickle cell disease. The role HbF  in  SCD was observed long back when it was 
noticed that infants with  SCD do not  have symptomatic disease and it was attributed to high 
HbF levels present during early infancy. The increased HbF levels are associated with a 
decreased rate of acute pain episodes, less osteonecrosis, fewer leg ulcers, and lesser frequency 
of acute chest syndromes as well as reduced disease severity. However, the level of HbF do not 
show a clear association with complications like  priapism, proteinuria, stroke and silent cerebral 
infarction, systemic hypertension, and pulmonary hypertension. The HbF level in SCA varies 
from 2-8% but varies with various beta gene haplotype.(67) 
 The two main properties of HbF which are considered to ameliorate SCD symptoms include: 
 
 
26 
 
1. HbF molecules do not participate in polymerization that occurs between molecules of 
deoxyHbS which results in decreased polymerization and in turn milder clinical 
phenotype. 
2. The higher concentration of HbF in a cell infer lower concentrations of HbS which in 
turn decreases polymerization.(66) 
The various factors that affect the level of HbF include the haplotype of beta gloobulin gene 
cluster, polymorphism at various quantitative trait loci (QTL) such as HBS1L-MYB intergenic 
region ( HMIP) region and BCL11A (2p16). (67) 
2.Alpha Thalasesemia: 
Concurrent alpha thalassemia has been found in approximately 30% of patients with SCD and is 
considered a modifier of sickle cell disease severity. SCD patients who have coincidental alpha 
thalassemia have lesser hemolysis and overall milder clinical phenotype. Alpha-thalassemia 
decreases mean corpuscular volume, increases hematocrit and reduce the concentration of HbS 
and HbS Polymerization. Vaso-occlusive events that are highly dependent on hematocrit, such as 
stroke, leg ulcer and splenic function, appear to benefit from the coexistence of alpha-
thalassemia. In contrast, adult patients with SCA with alpha thalassemia usually do not have a 
reduction and may have an increase in certain complications like painful episodes, acute chest 
syndrome and avascular necrosis, and is attributed to increased blood viscosity as a result of  
higher hematocrit resulting from associated alpha thalassemia mutation.(68) 
3.Hemoglobin Haplotype of Beta globulin (HBB gene like cluster): 
The other potential modulator of sickle cell disease phenotype is haplotype of beta globulin gene. 
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The HbS beta globulin gene is found in five common haplotypes, described as polymorphic 
restriction endonuclease sites in and around the mutant ß-globin gene. Although haplotypes have 
numeric identifiers, they are most commonly designated by the geographic areas in which they 
were first identified: Senegal, Benin, Central African Republic (or Bantu), Cameroon and Saudi-
Indian (or Asian). Carriers of the HbS gene on Senegal or Saudi-India haplotype usually have the 
highest HbF level and PCV and the mildest clinical course. Individuals with Bantu (Central 
African Republic) haplotypes have the lowest HbF level and PCV and the most severe clinical 
course. The carriers of all haplotypes have considerable variation in HbF levels, which suggests 
the importance of other quantitative trait loci (QTL) in modulating beta globulin gene 
expression.(67) 
4.Genetic Polymorphism 
Neither HbF level nor beta globin genotype can completely explain the clinical and laboratory 
diversity of SCD. Both HbF and alpha thalassemia affect the phenotype of disease by decreasing 
the polymerization of HbS. In a study of 1265 SCD patients with either "severe" or "mild" 
disease based on a defined model of disease severity, a genome-wide association study (GWAS) 
found 40 single nucleotide polymorphisms (SNPs) were strongly associated with sickle SCD 
severity  (with an odds for association >1000). Of these, 32 SNPs were further analyzed in a 
separate set of 163 SCD patients, five were replicated, eight showed consistent effects but  failed 
to reach statistical significance and 19 did not show any conclusive association.(69) 
The polymorphic genes that are thought to be important in phenotypic variability of SCD include 
genes involved in TGF-β/BMP pathway.(66) 
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VI. Management of SCD and Role of Hydroxyurea: 
The management of SCD includes diagnosis, prevention and treatment of its complications and 
potential cure of this illness and is briefly described below. 
1.Diagnosis 
The diagnosis of SCD essentially consists of  analysis of hemoglobin which can be done by 
protein electrophoresis or by chromatography. The various diagnostic tests include peripheral 
smear review, sickle solubility test, Hb electrophoresis, High Performance Liquid 
Chromatography (HPLC) and DNA based tests to detect the specific mutation. The type of test 
used depends upon the age of the patient as well as clinical scenario. DNA based tests are used in 
prenatal diagnosis and in patient with recent history of blood transfusion, while HPLC in 
combination peripheral smear review and sickle solubility test is used in most of the other 
patients. The neonatal screening programmes are in place in certain countries like US and 
England and leads to early diagnosis of SCD.  The electrophoresis at alkaline pH (cellulose 
acetate electrophoresis) or at acidic pH (Citrate agar electrophoresis) combined with sickle 
solubility test allows definitive diagnosis of SCD. (70). 
The HPLC is highly precise and automated technique for identification and quantification of 
hemoglobin. This technique detects most hemoglobin variants by their different retention times. 
It is highly sensitive as well as  specific and provides both the quantitative and qualitative 
interpretation .(70) 
The measurement of HbA2 is valuable for diagnosis of compound heterozygous sickle beta 
thalassemia as it is increased in such cases. However, it should be noted that HbA2 may be 
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overestimated in presence of HbS and in some cases familial studies and/or DNA based test may 
be required for the confirmation of diagnosis.(70)  
2.General Overview and Prevention of Complications: 
The management of SCD requires needs comprehensive care, team management along with 
education of the patients and their family members. It needs careful monitoring of growth and 
development in children and needs early detection of complications. The various primary 
preventive measures includes routine health management, use of penicillin prophylaxis, 
immunizations, and regular blood transfusions for certain patients. The only US Food and Drug 
Administration (FDA) approved therapy for prevention of various complications of SCD is the 
use of hydroxyurea which reduces sickle hemoglobin polymerization process by increasing the 
production of HbF levels .(71)  
 The penicillin prophylaxis should be started in all children at diagnosis and continued till at least 
till five years of age as children are at high risk of sepsis especially invasive pneumococcal 
disease due to functional asplenia.(71) 
  In 2012 Cochrane review by Riddington C et al, data from three such trials  (457 patients of 
SCD) was analyzed . As compared with placebo or no treatment, the penicillin prophylaxis was 
associated with a reduced risk of pneumococcal infection (odds ratio 0.37; 95% CI 0.16-0.86) as 
well as decreased risk of death (odds ratio 0.11; 95% CI 0.01-2.11). (72) 
The immunization forms the cornerstone of infection prevention in SCD patients. Children with 
sickle cell disease should receive all routine vaccines especially against pneumococcus, 
Meningococcus, Haemophilus influenzae and hepatitis B. (71). The use pneumococcal 
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vaccination has led to significant decrease in incidence of invasive pneumococcal disease in 
children with SCD. (50) 
3. Blood Transfusion and Chelation Therapy: 
Blood transfusion is used both for prevention as well as treatment of SCD related complications. 
The phenotype may vary transfusion dependent anemia requiring regular blood transfusions to 
chronic anemia with occasional acute drop in hemoglobin requiring blood transfusion. The role 
regular blood transfusion in prevention of certain complications like stroke in children is well 
established. However, blood transfusion carries the risks as well and the risk benefit ratio should 
be carefully assessed in these situations.(73) 
The prophylactic blood transfusion has been advocated in primary and secondary prevention of 
stroke, silent cerebral infarcts, and preoperative management and in patients with chronic anemia 
requiring regular transfusions. (73). 
In a study by Adam RJ et al, 130 children with sickle cell anemia and Trans Cranial Doppler 
(TCD) velocity of more than 200cm/sec on two occasions with no prior history of stoke were 
randomly assigned to institution of prophylactic transfusion to decrease HbS concentration 
below 30% or regular standard care. The study was prematurely terminated after 20 months of 
follow because of marked benefit to prophylactic transfusion group(10 cerebral infarctions and 1 
intracerebral hemorrhage in the control  group, as compared to1 infarction in the transfusion 
group  (P<0.001)). (74) 
The blood transfusion may be given for treatment of various complications of SCD and includes 
acute splenic sequestration, aplastic crisis, acute chest syndrome and acute symptomatic anemia . 
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The other less frequent indications of chronic blood transfusion therapy in SCD patients include 
recurrent ACS despite on hydroxyurea, severe recurrent acute painful crisis not responding to 
hydroxyurea, recurrent priapism and third trimester of pregnancy.(73) 
In SCD patients requiring blood transfusion for decreasing the level of HbS, simple blood 
transfusion may not be appropriate as it will be associated with increased blood viscosity and 
may not decrease the HbS to desired level. In such cases, exchange transfusion is done which 
involves removing of patients’ blood and then replacing it with exogenous blood.  Exchange 
transfusion has been found to be more beneficial in case of stroke, respiratory failure and multi 
organ failure.(75) 
The initiation of chelation therapy in  SCD patient dependents upon the number of transfusions 
given, the degree of hepatic and cardiac iron deposition in the amount of their dysfunction 
present, and the type of transfusion regime. The chelation therapy is recommended when Serum 
Ferritin  is more than 1000 microgram/L , Liver Iron Concentration is more than 7 mg/g dry 
weight and cumulative transfusions of more than 120 cc of packed RBCs/kg .(76) 
4. Pain management: 
The acute painful episodes are the most common cause for patients with SCD to seek medical 
attention. The treatment  consists of aggressive pain relief including the use of opiates, other 
analgesics, or even other modalities. In addition, exclusion of causes other than vasoocclusion 
(particularly infection), optimal hydration by oral or intravenous fluid resuscitation (especially in 
children) is also important. Blood transfusion may be required in patients having  hemodynamic 
instability and there is no role of blood transfusion to decrease the severity of pain. The acute 
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pain episodes can be managed at home or hospital depending upon the severity.  In hospital 
parentral opiod analgesia should be started and dose titrated as per the response.(77) 
5. Cure: 
A life-long cure for SCD is available only through hematopoietic stem cell transplantation 
(HSCT) and its use in SCD is evolving. However, hematopoietic stem cell transplant has been 
primarily used in children with severe phenotype where HLA identical sibling has been 
available; there is scarcity of data regarding the use transplant with alternative donor or adult 
patients with SCD. 
Historically only myeloablative conditioning regimens have used for HSCT which were 
associated increased complications especially in adults. However ,in a study by Mathew M eta 
al, 30 patients with SCD were given non myeloablative conditioning with Alemtuzumab, total 
body irradation (300cGY) and sorafenib, after median follow up of 3.4 years, 87% of patients 
had long term stable donor engraftment without acute or chronic graft versus host disease.(78) 
 
Role of Hydroxyurea: 
The hydroxyurea, first synthesized by Dressler and Stein in 1869 in Germany, is a small 
molecule that inhibits DNA synthesis by blocking to ribonucleotide reductase. This drug was 
first tested for solid organ malignancy and in subsequent decades, it was used for multitude of 
diseases including chronic myeloid leukemia, psoriasis, ovarian carcinoma and polycythemia 
vera.(79) 
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In 1984 hydroxyurea was first time in adult patients with SCD as it was found to increase HbF 
levels and subsequently in 1998, FDA approved the use of hydroxyurea in symptomatic adult 
sickle cell patients. The increased HbF concentration within RBCs results in less polymerization 
of abnormal hemoglobin.(79)  
In  landmark study, The Multi Centre Study of Hydroxyurea in Sickle Cell Anaemia (MSH) by 
Charache et al, 299 adult symptomatic sickle cell patients(defined as three or more painful crisis 
per year) were evaluated in a randomized controlled trial. 152 patients were assigned to 
Hydroxyurea (HU group) while 147 were assigned to placebo group and were followed for an 
average of 21 months. . The hydroxyurea use was associated with significant reduction in painful 
crisis(4.5 per year to 2.5 per year) along with marked reduction in incidence of acute chest 
syndrome (25 vs. 51, P<0.001) and blood transfusions(48 vs. 73, P< 0.001). The starting dose of 
hydroxyurea was 15mg/kg up to a maximum tolerated dose of 35mg/kg. There were no 
significant side effects of hydroxyurea use in this trial. (80) The 9-year follow up of same study 
revealed 40% reduction in the mortality among those who received hydroxyurea. The survival 
was associated with HbF level and frequency of painful episodes.(81) 
After the successful use of hydroxyurea in adults with severe symptomatic SCD, its use in 
pediatric patients was explored. In a study by Ferster A, 25 children with SCD with a mean age 
of 9 years were randomized to treatment with 15mg/kg of hydroxyurea for six months or placebo 
and then switched to other arm for six months. Out of 22 evaluable patients, 16 showed complete 
resolution of symptoms requiring hospitalization during treatment period(73% reduction).(82) 
In a pilot study by Winfred C et al, 28 children with SCD with a median age of 15 months were 
administered 20mg/kg/day of hydroxyurea to assess the feasibility and use in infant population. 
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After the two years of follow up, authors concluded that hydroxyurea use is feasible in infants 
and may delay organ dysfunction. The subsequent follow up of same study after four years 
revealed decreased incidence of acute chest syndrome(7.5 versus 24.5 in historical controls per 
100 patient years),better splenic function and improved growth. A further follow up of same 
cohort after about mean follow up of fifteen years have sustained clinical and hematological 
benefit of hydroxyurea with no significant side effects.(83,84,85) 
In a study by Winfred C et al, 193 children aged between 9-18 months with SCD were 
randomized (98 to hydroxyurea group and 97 to placebo) to either receive hydroxyurea 
20mg/kg/d or placebo for a period of two years. the primary end points were assess organ 
dysfunction, clinical complications and toxicity of treatment. After the mean follow up of two 
years, there was no significant differences between the groups for the organ dysfunction (19 out 
of 70 had decreased spleen function in the hydroxyurea group versus 28 out of 74 patients in the 
placebo group, p=0·21; and the difference in the average increase in DTPA glomerular filtration 
rate in the hydroxyurea group versus the placebo group was  2 mL/min per 1·73 m2, p=0·84). 
However, use of hydroxyurea significantly decreased acute  painful episodes  (177 events in 62 
patients in HU group versus 375 events in 75 patients in  placebo group, p=0·002) and dactylitis 
(24 events in 14 patients versus 123 events in 42 patients in  placebo group, p<0·0001), with 
some evidence for decreased frequency of  acute chest syndrome, hospitalization rates as well as  
transfusion. Hydroxyurea use increased hemoglobin and fetal hemoglobin, and decreased 
leucocyte count. The toxicity  noted was limited to mild-to-moderate neutropenia.(86) 
The current guidelines recommend the use of hydroxyurea in adults with 3 or more severe 
vasoocclusive crises per year,  chronic pain or chronic anemia interfering with activities of daily 
living , or patients having severe or recurrent episodes of acute chest syndrome. In children 
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treatment with hydroxyurea is suggested in symptomatic older children as well as in 
asymptomatic infants (after the age of 9 months). (71, 87) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims & Objectives 
 
 
 
36 
 
Aims and objectives: 
1. To analyze the demographic, clinical and laboratory profile of patients (adults and children) 
with sickle cell disease. 
2. To assess the use and response to hydroxyurea in these  patients. 
3. To identify the demographic, clinical, and laboratory parameters that can 
predict response to hydroxyurea in these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients & Methods 
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Patients and Methods:  
This study protocol was approved by our Institutional Review Board (IRB). 
This study involved a retrospective analysis of patients with sickle cell disease from 2005-2013 
who were treated in Department of Clinical Haematology 
 
Duration of the study: June 2014 to December 2014. 
 
Settings of the study: Department of Clinical Haematology. 
 
Diagnostic Criteria: 
       Sickle cell disease was  diagnosed in patients by either of the following methods: 
1) Hemoglobin variant analysis done by High performance Liquid 
Chromatography (HPLC) showing either homozygosity for HbS or HbS beta 
thalassemia.(70) 
2) Hemoglobin mutation analysis  done by reverse dot blot technique revealing 
either homozygous HbS or HbS beta thalasemia.(70) 
Inclusion criteria: 
1. All the patients seen and diagnosed as having sickle cell disease (homozygous 
sickle cell and sickle beta thalassemia) and have had atleast six months of 
subsequent follow up were included in the study. 
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Exclusion criteria: 
1. Patients with other hemoglobinopathies. 
2. Patients with follow up duration < 6 months or no follow up or where the data 
was not retrievable. 
 
Collection of data:  
After approval by the Institution Review Board, the patient data base at our institution was 
reviewed to identify all patients (adults and children) diagnosed and treated for sickle cell disease 
at our institute from January 2005 to December 2014. Medical information regarding the 
clinical/laboratory details at diagnosis, post treatment response and adverse events were obtained 
from the hospital records (laboratory reports/ physician documentation in hospital charts/hospital 
discharge summaries). 
Only patients who had at least six months follow up after starting  treatment  were categorized as 
‘evaluable‘ for assessment of response. 
Treatment: All patients who were diagnosed with sickle cell disease and had adequate follow up  
were included in the study. Data was collected with regard to demographic ,clinical and 
laboratory profile of the patients, use of hydroxyurea , assessment of its response as well as 
adverse events were noted. The dose of hydroxyurea varied from 10mg/kg/day to 35mg/kg/day 
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Data analysis:  
Results are analyzed in terms of the demographic, clinical characteristics and laboratory 
parameters at diagnosis, and at different time interval after starting of Hydroxyurea therapy. The 
response to treatment is assessed in terms of Complete Response (CR), Partial response (PR) and 
No response.  The CR in sickle cell disease was defined as complete resolution of presenting 
symptom while partial response was defined as at least 50% reduction in frequency of presenting 
symptoms. The diagnosis of anemia was done as per the WHO definition. (88) 
 The following parameters were analyzed  
a) Demographic, clinical, and laboratory profile at diagnosis 
b) Frequency of presenting symptom and changes in laboratory parameters like HbF 
after three and six months of hydroxyurea treatment. 
c) Frequency of symptoms at last follow up 
d) Dose, compliance, response and adverse events to hydroxyurea therapy 
All patients with a minimum  follow up of six month were considered evaluable 
for response . The closing date for analysis was March 31, 2015. 
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STATISTICS 
Descriptive statistics were calculated for all variables. Differences in proportions and two 
categorical variables were assessed using the chi-square test. Mann-Whitney-U test was used 
to compare two continuous variables.  For all tests, a 2-sided P-value of 0.05 or less was 
considered statistically significant. SPSS 16.0 software was used for the analysis.  
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RESULTS 
From January 2005 to December 2013, a total of 9389 patients were evaluated in department of 
Clinical Haematology for suspected hemoglobinopathy by hemoglobin variant analysis or 
thalassemia mutation analysis (or both where appropriate). Of these, 745(7.9%) were diagnosed 
as sickle cell disease (consisting of homozygous sickle cell disease and compound heterozygous 
sickle beta thalassemia). Out of this, only 230 patients had adequate follow up and were included 
in present study. 
There were total of 230 patients of sickle cell disease who fulfilled the inclusion criteria and 
were included in this study for analysis. (Figure 1) 
Certain data was available only on a portion of the patients. For each result therefore, the 
numbers of patients included are mentioned accordingly. 
 
 
DEMOGRAPHY PROFILE AT DIAGNOSIS: (Table: 1) 
The median age of the 230 patients was at the time of evaluation was 12 years (range: 1-54 
years), while median age at which first symptom occurred was 4 years (1-54 years). Males were 
predominantly represented in the study group i.e. 152 (66.1%) males and 78 (33.9%) females. 
The male female ratio was 1.9:1. They were patients from different states of the country and two 
patients from outside country (Maldives). (Figure 2) 
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The family history of similar illness was present in 36(15.7%) patients while majority of patients 
(n-194, 84.3%) had no history of any such illness in family 
SYMPTOMS AT DIAGNOSIS AND OVERALL FREQUENCY OF VARIOUS 
COMPLICATIONS: (Table No.2 and Table No.3a and Table No.3b) 
The bone pain was the most common symptom and was present in 187(81.3%) and was the only 
symptom in 93 patients (40.4%). Anemia as defined by WHO criteria (as described above) was 
present in 227(98.6%) patients while symptomatic anemia was presenting symptom in 125 
patients (54.5%) out of which 10 patients (4.3%) were having transfusion dependent anemia. In 
addition, patients presented with combination of pain and anemia (68 patients, 29.6%). The 
symptoms combinations at diagnosis were joint pain and avascular necrosis in 11 patients (4.8%) 
and pain, anemia and avascular necrosis in two patients (0.9%). History of blood transfusion was 
present in 167(72.6%) patients. Other clinical features which were present at diagnosis included 
abdominal pain in 28(12.2%), jaundice in 14(6.1%) and febrile episodes in 17(7.4%). 
Splenomegaly was present in 115 patients (50%) with an average size of 3.7cm (range 2-9cm) 
below left costal margin. 
 A number of complications were detected in our cohort of patients at diagnosis or during the 
period of follow up. This included avascular necrosis of femur head in 32 patients (13.9%), 
cholilithiasis in 14(6%) and acute chest syndrome in 14 (6.1%). Various infections were 
documented in 11 patients (4.7%) and this included osteomyelitis (n-5), septic arthritis (n-2), 
pneumonia (n-2) and urinary tract infections (n-2). The lesser common complications detected 
during follow up included chronic leg ulcer in 3 patients (1.3%), seizure disorder in 2 patients 
(0.8%) and stroke in 2 patients (0.8%)   
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LABORATORY PARAMETERS AT DIAGNOSIS (Table No.4) 
Out of 230 patients, majority of the patients [n=227(98.6%)] were found to have anemia (as per 
WHO defined criteria). The median hemoglobin at presentation for the entire cohort was 8.7g/dl 
(range: 4-12.5g/dl). The white cell count was available for 229 patients and median WBC count 
was 11660/mm3 (range: 2100-39600). The median corpuscular volume in 223 patients (where 
data was available) was 80.6fl (range: 57.7-108.2fl). 
The reticulocyte count was available in 218 (94.7%) patients and median reticulocyte percent for 
these patients was 7.06% (range: 0.69-23.76). The median platelet count at presentation was 
274448/ mm3 (range: 11000-3449000). The percentage of Hemoglobin F and Hemoglobin S at 
diagnosis was available for 182 patients (79.1%). The median HbF percent was 19.5 (range: 4.7-
54%) while median HbS percent at diagnosis was 72.2 (range: 28-87%). 
Using a combination of variant analysis (n = 182) and RDB (n = 48), 148 patients (64.3%) were 
diagnosed to have homozygous sickle cell disease while 82 patients (35.6) had sickle beta 
thalassemia 
TREATMENT AND RESPONSE (Table No.5 and Table No. 6) 
Among the total 230 patients included in the study, 222 (96.5%) were treated with hydroxyurea, 
while 8 (3.5%) were kept under regular follow up and hydroxyurea was not started in view of 
minimal symptoms. 
The median dose of hydroxyurea used was 15mg/kg/day (range: 10-35mg/kg/day). The response 
to therapy was assessed 6 months and at last follow up.  
 
 
44 
 
Adverse events to hydroxyurea use were noted in 17 patients (7.6%) and included leucopenia in 
10 patients (4.5%), thrombocytopenia in 4 patients (1.8%) and marrow aplasia in one patient 
(0.4%). There were no deaths related to the use of hydroxyurea. One patient with bone marrow 
aplasia had full recovery of blood counts after about one year of observation. 
The response assessment was done in terms of resolution of/or decrease in frequency of 
presenting symptoms and were defined in terms of complete response, partial response and no 
response (as described above). 
At six months of follow, data for three patients was lacking and out of the 219 patients evaluable 
for response, 170 patients (77.6%) showed complete response, 43 patients (19.6%) showed 
partial response and there was no response in 6 patients (4%). 
At last follow up, with median duration of 36.25 months (range 6-117months), 131 patients 
(57.4%) showed complete response while 86 patients (37.4%) showed partial response and only 
5 patients (2.2%) did not show response to hydroxyurea. 
EFFECT OF HYDROXYUREA ON CLINICAL AND LABORATORY PARAMETERS 
(Table No.7) 
The comparison of clinical and laboratory parameters at diagnosis and after treatment with 
hydroxyurea for median duration of 36.25 months showed significant decrease in annual 
frequency of painful episodes from 3.4±1.3 to 0.9±0.49 (p=0.000), blood transfusion requirement 
from 4 units(±2.3) to 1unit(±0.25) and episodes of acute chest syndrome from 6.3% to 
1.8%(p=0.01). There was significant increase in hemoglobin (g/dl) from 8.7±1.44 to 9.6±1.45 
(p=0.000) and in 34 patients where pre and post treatment HbF values were available, mean HbF 
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(%) increased from 18.3±6.6 to 25.9±10.06 (p=0.000). The mean leucocyte count decreased from 
11.71x103 to 9.0±103 (p=0.000) 
SURGERY RELATED VARIABLES AND OUTCOME IN SCD PATIENTS (Table No.8) 
There were 33 surgeries performed in 230 patients during the median follow up of 36.25 months 
(6-117 months). Out of these 27 surgeries were performed at CMC hospital and were further 
analyzed for various variables and outcome. Majority were orthopedic surgeries for avascular 
necrosis of femoral head and included hip arthroplasty and core decompression (16 patients - 
59.2%). Other surgeries included cholecystectomy in 4(14.8) and splenectomy in 4(14.8). In 
addition, mitral valve replacement, hepaticojejunostomy and lower segment cesarean section 
were performed in 1 patient each. Most patients were managed with simple blood transfusion in 
perioperative period, given in 24 patients (88.8%) while 6 patients (25.9%) required exchange 
transfusion prior to surgery. Of the 6 patients who had exchange transfusion prior to surgery, 4 
patients required perioperative blood transfusion as well (Median 1 unit; range 1-3units). Out of 
27 patients, 2 patients did not require any blood transfusion or exchange transfusion. 
Postoperative complications occurred in 4 patients (14.8%) and included pneumonia/acute chest 
syndrome in one patient while other patients had complications unrelated to sickle cell disease 
(hematemesis in one patient, increased blood loss during surgery in one patient and urinary tract 
infection in one patient). Post-operative ICU care was required in 4 patients (14.8%) and there 
were no deaths reported. 
 
 
 
 
 
46 
 
COMPARISON OF HOMOZYGOUS SICKLE AND SICKLE BETA THALASSEMIA:  
A. CLINICAL PARAMETERS (Table No.9 and Table No.10)  
Out of 230 patients, 148 patients (64.3%) had homozygous sickle cell disease while 82 patients 
(35.6) had sickle beta thalassemia. In homozygous sickle cell anemia, 91 patients (61.5%) were 
males and 57 patients (38.5%) were females. In sickle beta thalassemia, 61 patients (74.4%) were 
males while 21(25.6%) were females. 
There were no statistically significant differences in age at first symptom (4 years in both, 
p=0.5), however, the age of evaluation was 9 years in patients with sickle beta thalassemia as 
compared to 14 years in patients with homozygous sickle cell disease (p=0.03).  
The most common symptom in both groups was acute painful episodes and was present in 123 
patients (83.1%) with homozygous sickle and 64 patients (78%) with sickle beta thalassemia 
(p=0.37). There were no statistically significant differences with respect to frequency of anemia 
(98 versus 54, p=1.00), avascular necrosis (23 patients versus 8 patients, p=0.33), acute chest 
syndrome (12 patients versus 2 patients, p=0.14) and cholilithiasis (12 patients versus 2 patients, 
p=0.14). However, there was significantly higher incidence of splenomegaly in patients of sickle 
beta thalassemia as compared to homozygous sickle cell disease (37% versus 73%, p=0.00). 
B. LABORATORY PARAMETERS (Table No.11)  
In comparison to homozygous sickle cell anemia, the hemoglobin at diagnosis was lower in 
sickle beta thalassemia, but the difference was not statistically significant (9.1g/dl versus 8.6g/dl, 
p=0.15). The mean corpuscular volume was significantly higher in patients of homozygous 
sickle cell anemia as compared to patients of sickle beta thalassemia (86.6fl versus 70fl, p=0.00). 
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The mean WBC count was higher in patients of homozygous sickle cell anemia (11500/mm3 
versus 9550/mm3, p=0.003) and mean reticulocyte percent was higher in patients of homozygous 
sickle cell anemia (6.8% versus 5.2%, p=0.001). In 182 patients (120 of homozygous sickle cell 
disease and 62 of sickle beta thalassemia), where data for HbF and HbS was available for both 
groups, patients with homozygous sickle cell anemia had higher levels of HbS (73.2% versus 
70.4%, p=0.001), while HbF was similar in both groups (19.8% versus 19.2%, p=0.9). 
C. USE AND RESPONSE TO HYDROXYUREA (Table No.12 and Table No.13)  
Hydroxyurea was used in 145 patients (98%) with homozygous sickle cell disease whereas 77 
patients (93.9%) of sickle beta thalassemia were treated with hydroxyurea but the difference was 
not statistically significant (p=0.137). The median dose of hydroxyurea was similar in both 
groups (15mg/kg/day). The adverse events occurred in 12 patients (8.2%) with homozygous 
sickle cell anemia and in 4 patients (6.4%) with sickle beta thalassemia (p=0.6). 
Response assessment at six months of hydroxyurea therapy was available in 142 patients with 
homozygous sickle cell anemia (data was inadequate in 3 patients and were excluded from 
analysis and 77 patients with sickle beta thalassemia. At six months of hydroxyurea therapy, a 
significantly higher number of patients with  homozygous sickle cell disease showed complete 
response as compared to patients with sickle beta thalassemia [117 patients (82.4%) versus 53 
patients(68.8%)] (p=0.04) . In patients with homozygous sickle cell disease, 23 patients (16.2%) 
showed partial response while 2 patients (1.4%) showed no response at six months assessment of 
hydroxyurea use. In patients with sickle beta thalassemia, 20 patients (26%) showed partial 
response and 4 patients (5.2%) showed no response to hydroxyurea. 
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Long term response assessment was done at a median duration of 36.25 months (Range: 6 - 117). 
88 patients (60.6%) with homozygous sickle cell disease showed complete response, 55 (37.9%) 
showed partial response while 2(1.4%) showed no response to hydroxyurea therapy. In patients 
with sickle beta thalassemia, 43 patients (55.8%) showed complete response, 31 patients (40.3%) 
showed partial response while 3 patients (3.6%) did not show any response to hydroxyurea 
therapy. The difference in response between the two groups was not statistically significant. 
(p=0.4) 
FACTORS PREDICTING RESPONSE TO HYDROXYUREA TREATMENT (Table No. 
14 and Table No.15) 
In the present study, all patients who showed response (either PR or CR) were considered as 
responders even if they were subsequently lost to follow up. The response was defined as 
complete response (CR) if there was complete resolution of presenting symptom after 
hydroxyurea therapy, partial response (PR) if there was at least 50% reduction in presenting 
symptom and those who did not show response till last follow up were considered as non-
responders (NR). A detailed analysis was done of factors affecting the complete response. 
However a significant association was observed with higher hemoglobin (p= 0.03), low 
reticulocyte percent (p=0.03) and higher HbF percent (p=0.01) at diagnosis. In addition, 
increased level of HbF at last follow up were associated with complete response (p=0.004) No 
significant association was found with age at presenting symptom (p=0.143), gender (p=0.112), 
homozygous sickle cell anemia versus sickle beta thalassemia (p=0.546), presenting symptom at 
diagnosis (p=0.154), leucocyte count (p=0.06), or platelet count (p=0.140) at diagnosis with the 
response status.  
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Tables and Figures 
Table No.1: Demographic Profile of Patients (n-230) 
Variable N(%)/median(range) 
 
Age at evaluation(years) 
 
Age at first Symptom 
 
 
12(1-54) 
 
4(1-54) 
Gender  
 
       Male 
 
       Female 
 
 
152 (66.1) 
 
78 (33.9) 
 
Family History 
   Present 
  Absent 
 
36(15.7) 
194(84.3) 
State 
 
Andhra Pradesh 
 
Bihar 
 
Orissa 
 
Jharkhand 
 
Chhattisgarh 
 
Tamil Nadu 
 
West Bengal 
 
Others* 
 
 
 
44(19.1) 
 
2(0.9) 
 
23(10) 
 
72(31.3) 
 
14(6.1) 
 
36(15.7) 
 
23(10) 
 
16(7) 
*Includes two patients from Maldives. 
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Table No.2: Symptoms at Diagnosis (n-229)* 
Variable N (%) 
 
 Pain 
 
 
93(40.4) 
 
Symptoms of Anemia 
  Transfusion dependent anemia 
 
 
55(20.9) 
10(4.3) 
 
Pain and Avascular necrosis(AVN) 
 
11(4.8) 
 
Pain and anemia 
 
68(29.6) 
 
Pain, AVN and anemia 
 
2(0.9) 
*One case was asymptomatic and was diagnosed screening in view of family history of sickle 
cell disease. 
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Table no.3a Overall frequency of clinical features  (n-230) 
 
Variable N (%) 
 
acute painful episodes 
 
187(81.3) 
 
Anemia* 
 
227(98.6) 
 
Blood Transfusions  
 
167(72.6) 
 
Abdominal Pain 
 
28(12.2) 
 
Febrile episodes 
 
17(7.4) 
 
Jaundice 
 
14(6.1) 
 
Splenomegaly 
 
115(50) 
*As per WHO defined criteria 
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Table no.3b Overall frequency of Complications (during follow up)(n-230) 
Variable N (%) 
Avascular necrosis 32(13.9) 
Acute chest syndrome 14(6.1) 
Cholilithiasis 14(6) 
Infections 
    Osteomyelitis 
   Septic arthritis 
   Pneumonia 
  Urinary Tract Infections 
11(4.7) 
5(2.1) 
2(0.9) 
2(0.9) 
2(0.9) 
 
Leg Ulcer 
 
3(1.3) 
 
Seizure disorder 
 
2(0.9) 
 
Stroke  
 
2(0.9) 
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Table No. 4 Laboratory Parameters at Diagnosis 
Variable Mean(range) 
Hemoglobin(g/dl) 
(n-230) 
8.7(4-12.5) 
Mean corpuscular volume 
(n-223) 
80.6(57.7-108.2) 
WBC count(x103cells/mm3) 
(n-229) 
11.6(2.1-39.6) 
Platelet ((x103cells/mm3) 
(n-228) 
274(11-344) 
Reticulocyte (%) 
(n-218) 
7.06(0.69-23.76) 
HbF(%) 
(n-182) 
19.5(4.7-54) 
HbS(%) 
(n-182) 
72.2(28-87) 
Creatinine(mg/dl) 
(n-212) 
0.5(0.2-1.3) 
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Table no 5 Use of hydroxyurea 
Variable N(%)/median(range) 
Hydroxyurea  
      Yes 
      No 
   
 
222(96.5) 
8(3.5) 
Dose(mg/kg/day) 15(10-35) 
Adverse Events 
  Leucopenia 
  Thrombocytopenia 
  Aplasia 
  
17(7.6) 
10(4.5) 
4(1.8) 
1(0.4) 
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Table No.6 Response to Hydroxyurea 
Response  At 6 months(n-219) 
      CR 
      PR 
     NR 
 
 
170(77.6) 
43(19.6) 
6(2.7) 
 
Response  At last follow up(n-222) 
     CR 
     PR 
     NR 
 
 
131(57.4) 
86(37.4) 
5(2.2) 
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Table No.7 Effect of Hydroxyurea on clinical and laboratory parameters (n-222) 
Variable At diagnosis 
Mean (±SD)/n(%) 
After HU therapy 
(At last follow up) 
Mean (±SD)/N(%) 
P value 
 
Bone and Joint pain(episodes/year) 
 
3.4(1.3) 
 
0.9(0.49) 
 
0.000 
 
Blood transfusion (units/year) 
 
1.7(2.0) 
 
1(0.25) 
 
0.000 
 
Acute chest syndrome (no. of episodes) 
 
14(6.3) 
 
4(1.8) 
 
0.01 
  
Hemoglobin(g/dl) 
(n-220) 
 
8.7(1.44) 
 
9.6(1.45) 
 
0.000 
 
WBC count(x 103 cells/mm3) 
(n-220) 
 
11.71(5.5) 
 
9.0(3.8) 
 
0.000 
 
Mean corpuscular volume(fl) 
(n-215) 
 
80.48(11.11) 
 
88.58(15.9) 
 
0.000 
 
HbF(%)  (n-34) 
 
 
18.3(6.6) 
 
25.9(10.06) 
 
0.000 
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Table.No.8 Surgery related variables and outcome in SCD patients (n-27) 
Variable   N (%) 
Type of surgery 
   Hip Arthroplasty 
   Cholecystectomy 
   Splenectomy 
   Others* 
   
 
16(59.2) 
4(14.8) 
4(14.8) 
3(11.11) 
Simple blood transfusion 
        Yes 
        No 
 
23(85.2) 
4(14.8) 
Exchange Transfusion 
     Yes 
     No 
    
 
6(25.9) 
21(77.7) 
  ICU care(perioperative) 
  Yes 
  No 
 
4(14.8) 
23(85.1) 
 Complications 
    Sickle cell related(pneumonia/?ACS) 
     Others 
Death 
4(14.8%) 
1 
3 
0 
*Includes one LSCS, one mitral valve replacement and one Hepaticojejunostomy 
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Table No.9 Classification 
Variable N (%) 
 
Homozygous sickle cell disease 
 
148(64.4) 
 
Compound heterozygous sickle beta 
thalassemia 
82(35.6) 
 
Table No.10 Comparison Between homozygous sickle cell and sickle beta thalassemia 
A. (Clinical parameters) 
Varaible Sickle cell anemia(n-148) 
N(%)/Median(range) 
Sickle beta thalasemia(n-82) 
N(%)/Median(range) 
P value 
Demographic Profile 
   Age (in years) 
       at first symptom 
      at evaluation 
  Gender 
       Male  
     Female 
 
 
 
4(1-54)  
14(1-54) 
 
91(61.5) 
57(38.5) 
 
 
4(1-45) 
9(1-47) 
 
61(74.4) 
21(25.6) 
 
 
0.5 
0.03 
 
 
 
  Clinical Profile 
    Joint pain  
    Anemia 
 
123(83.1)   
98(66.2) 
 
64(78) 
54(65.8) 
 
0.37 
1.0 
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   Avascular necrosis 
   Acute chest syndrome 
  cholilithiasis 
  Splenomegaly 
             Yes 
             No 
 
23(15.5) 
12(8.1) 
12(8.1) 
 
55(37.1) 
93(62.9) 
8(9.8) 
2(2.4) 
2(2.4) 
 
60(73.1) 
22(26.9) 
0.33 
0.14 
0.14 
 
0.00 
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Table No.11 Comparison Between homozygous sickle cell and sickle beta 
thalassemia  
B. (Laboratory parameters at diagnosis) 
Variable Homozygous Sickle(n-148) 
Median(range)  
Sickle beta thalassemia(n-82) 
Median(range) 
p value 
Hemoglobin 9.1(4.8-12.5) 8.6(4-11.9) 0.15 
Mean corpuscular volume* 86.6(76-96.5) 70(57.7-79.2) 0.000 
WBC count(x 
x103cells/mm3) 
 
11.5(2.1-39.6) 9.5(3.6-38.4) 0.003 
Platelet count (x 
103cells/mm3) 
 
267(11-783) 262(129-344) 0.7 
Reticulocyte count 6.8(0.8-23.6) 5.2(0.6-23.7) 0.001 
HbF(%)** 19.8(7-35) 19.2(8.9-54) 0.9 
HbS(%)** 73.2(51-87) 70.4(45-78) 0.001 
*MCV data was available in 142 of homozygous sickle cell patients and 80 sickle beta 
thalassemia patients after exclusion of post transfusion samples. 
**HbF and HbS data was available in 120 patients of homozygous sickle cell anemia and 62 
patients of sickle beta thalassemia after exclusion of post transfusion samples. 
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Table No.12 Comparison Between homozygous sickle cell and sickle beta thalassemia 
(Use of hydroxyurea) 
Variable Sickle homozygous (n-145) 
N(%)/Median(range) 
Sickle beta thalassemia (n-77) 
N(%)/Median(range) 
P value 
Hydroxyurea  
    Yes 
    No   
 
 
145(98%) 
3(2%) 
 
 
77(93.9%) 
5(6.1%) 
 
0.137 
Dose (mg/kg/day) 
 
15(10-35) 15(10-30) 0.1 
Adverse Effects 
 Leucopenia 
 Thrombocytopenia 
  Aplasia 
 
12(8.2%) 
6 
3 
1 
5(6.4) 
4 
1 
0 
0.6 
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Table No.13 Comparison Between homozygous sickle cell and sickle beta thalassemia 
(Response to hydroxyurea) 
Response  At  6 months 
      CR 
      PR 
      NR 
 
n-142* 
117(82.4) 
23(16.2) 
2(1.4) 
 
53(68.8) 
20(26) 
4(5.2) 
 
0.04 
Response  At last f/u 
 
      CR 
      PR 
      NR 
 
 
 
88(60.6) 
55(37.9) 
2(1.4) 
 
 
43(55.8) 
31(40.3) 
3(3.6) 
 
 
0.4 
*Data was not available for three patients at six month follow up 
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TABLE NO.14 FACTORS PREDICTING RESPONSE TO HYDROXYUREA 
(Clinical Parameters) 
Variable CR(N-131) 
N(%)/Mean ±SD 
PR+NR(N-91) 
N(%)/Mean ±SD 
P value 
Diagnosis 
  Homozygous Sickle(n-145) 
 Sickle beta thalassemia(n-77) 
 
88(60.6) 
43(57.1) 
 
57(39.4) 
34(44.1) 
 
0.54 
Age at presenting symptoms 
( years) 
6.95(7.1) 6.21(7.1) 0.143 
Gender 
    Male(n-144) 
    Female(n-78) 
 
87(60) 
45(57.7) 
 
58(40) 
33(42.3) 
 
0.112 
 Symptoms 
   Bone and joint pain 
   Symptomatic anemia 
   Pain and anemia 
   Avascular Necrosis  
   
 
107(81.1) 
29(22.1) 
37(28.2) 
20(16) 
 
76(83.5) 
16(17.5) 
26(28.6) 
11(12) 
 
0.22 
0.15 
0.96 
0.56 
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Table No 15 TABLE NO.14 FACTORS PREDICTING RESPONSE TO HYDROXYUREA 
(Laboratory parameters- At diagnosis) 
Variable CR(n-131) 
N(%)/ Median(range) 
PR+NR(n-91) 
N(%)/ Median(range) 
Pvalue 
  Hemoglobin(g/dl) 
 
 Leucocyte (x103cells/mm3) 
 
  Platelet (x103cells/mm3) 
   
 Reticulocyte (%) 
9(4.5-11.9) 
 
10.2(2.1-396) 
 
233(129-653) 
 
5.8(0.68-23.6) 
 
8.3(6.2-11.4) 
 
12.1(3.4-38.4) 
 
280(11-3449) 
 
6.7(0.8-23.76) 
0.03 
 
0.06 
 
0.14 
 
0.03 
Mean corpuscular volume 
(n-216) 
82.5(57-108.2) 79.05(61.5-104.7) 0.21 
Hb F(%) 
(n-182) 
21(6.1-54) 17.6(4.7-33.3) 0.01 
HbS(%) 
(n-182) 
72.2(43-87) 72.8(38-87) 0.33 
*HbF(%) 
(n-34) 
32.05(20.5-51) 19.05(3.2-38.2) 0.004 
*HbF at last follow up 
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Figure no 1. Approach to patient selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
January 2005-July 2013 
Total number of hemoglobin variant analysis and 
thalassemia mutation analysis done 
                                   N-9389 
 
Total number patients diagnosed with sickle cell disease 
                                  N-745 
 
Excluded from study  
         (N=515) 
Not adequate follow up/ 
inadequate data available 
Included from study 
     N=230  
 
 
 
66 
 
Figure No. 2. Distribution of patient population 
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DISCUSSION 
Sickle cell disease is a multisystem disorder with wide variations in presentation and severity 
ranging from being minimally symptomatic to transfusion dependent anemia or severe pain 
crises which can be fatal. In the present scenario, the role of hydroxyurea, and in certain 
situations, regular blood transfusions have been well established in improving the quality of life 
and overall survival. However in Indian patients, where the disease manifestations are usually 
mild and baseline HbF is higher, the ideal therapy is not well defined. Here an attempt was made 
to study the demographic profile and response to hydroxyurea treatment patients of sickle cell 
disease who were diagnosed and treated in Christian Medical College, Vellore from January 
2005 - December 2013. 
During the study period, 745 patients (7.9%) were diagnosed as sickle cell disease (including 
homozygous sickle cell anemia and compound heterozygous sickle beta thalassemia) out of 9389 
patients evaluated for suspected hemoglobinopathy by hemoglobin variant analysis and 
thalassemia mutation analysis. This study includes 230 patients of sickle cell disease (out of 745 
patients of sickle cell disease) who fulfilled the inclusion criteria of present study. 
The median age of patients at evaluation was 12 years (range 1-54years), while median age of 
first symptom was 4 years (1-54years). The male: female ratio was 1.9:1 suggesting male 
preponderance. In comparison to other studies, our patients were older at the time of evaluation. 
In a study of 299 patients of sickle cell disease by Neonato et al (89), the median age at 
evaluation was 10.1 years (±5.8 years).  In a study from a tertiary care hospital in south India by 
Chandra et al, the median age at diagnosis was 19.9 years(range3-48 years), while a study from 
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another Centre in Karnataka, India, the median age of diagnosis was 8.5 years(range 1-50 
years).(90,91). The difference in age at evaluation could be due to referral bias as our study was 
carried out in tertiary care hospital with most of the cases belonging to other states. There were 
more male patients in our study which can be due gender bias prevalent in our country and has 
been noticed in other studies from India. 
In our study, majority of the patients were from Eastern India with 72 patients (31.3%) from 
Jharkhand, 23 patients (10%) from Orissa and 23 patients (10%) from West Bengal. There were 
36 patients (15.7%) from Tamil Nadu, 44 patients (19.1%) from Andhra Pradesh, 14 patients 
(6.1%) from Chhattisgarh and 2 patients (0.9%) from Bihar. In addition there were 14 patients 
(6%) from other states of India and two patients from Maldives. The various epidemiological 
studies have documented 0-18% prevalence of sickle gene in Eastern India.  Although the central 
and western India is having high prevalence of sickle gene (22.5-44.4% and 0-33.5% 
respectively), the paucity of patients from these regions can be explained on the basis of referral 
bias. (92) 
The bone and joint pain was the most common symptom in our study and was present in 187 
patients (81.3%) and was the presenting symptom in 93 patients (40.4%). In 55 patients (24%), 
symptoms of anemia was presenting feature, out of these, 10 patients (4.3%) had transfusion 
dependent anemia requiring regular blood transfusions. In addition, 68 patients (29.6%) 
presented with both symptomatic anemia and joint pain at the time of diagnosis. Other rarer 
presentation at diagnosis included bone and joint pain with avascular necrosis in 11 patients 
(4.8%) and symptomatic anemia, pain along with avascular necrosis in two patients (0.9%). The 
overall frequency of symptomatic anemia was 54.3% (n-125) while anemia (as defined by WHO 
criteria) was present in 98.6% (n-227) of patients. The overall prevalence of other clinical 
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features included abdominal pain in 12.2 % (n-28), febrile episodes in 7.4% (n-17) and jaundice 
in 6.1% (n-14). Splenomegaly was present in 50% (n-115) of patients at diagnosis. In a study of 
305 children of sickle cell disease diagnosed at birth, Bainbridge et al (93) noticed that acute 
painful episodes were most common presentation and was the most common symptom by two 
years of age and was present in 88% of patients. In a study by Chandra et al (90), 55 patients of 
sickle cell disease were prospectively studied and in their cohort of patients, symptoms at 
presentation included pain (80%), jaundice (85%) and anemia (60%).The splenomegaly was 
reported in 41% of their patients. The findings are similar to our study except for increased 
frequency of jaundice in their study. In another study from south India (Karnataka), Meera et al 
studied 60 patients of sickle cell disease and in their study anemia was most common symptom 
at presentation and was present in 83.3% of patients followed by bone pains present in 60% 
patients. (91) In comparison to our study, the symptomatic anemia was more prevalent than our 
cohort of patients while bone pains were less frequent as compared to our study. This can be 
explained both on the basis of phenotypic heterogeneity as sickle cell disease in known to have 
high phenotypic variability as well the patient population studied were different (East Indian 
versus natives of Karnataka). 
Abdominal pain and fever was present in 28 (12.2%) and 17 (7.4%) patients respectively. In a 
study by Jain et al, 85 children with sickle cell disease were prospectively analyzed for morbidity 
pattern and acute febrile illness was noted in 30% of patients and was common morbid event 
during the study. (94).The higher incidence of fever in their study can be due to that only the 
children less than five years of age were included in the study that are more prone to infection. In 
addition, data on follow up may not have been fully captured during follow up. 
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Avascular necrosis was present in 13.9% of our patients. In literature, the incidence of avascular 
necrosis is known to be about 10 % (46). In study by Chandra et al, AVN was present in 5.4% of 
patients while in another study by Meera et al, only one patient out of sixty (1.6%) was found to 
have AVN (90,91). The higher incidence of AVN in our study population can be because of 
referral bias as many patients are referred for surgical intervention to our hospital. 
Acute chest syndrome was present in 6.1% (n-14) of our patients. As compared to other studies 
from India, the incidence of acute chest syndrome has been reported in the range of 3.3% to 
10.9%. (90, 94) 
 In our study, 167 patients (72.6%) had past history of blood transfusion at the time of diagnosis. 
This is higher as compared to study by Chandra et al (52% versus 72%), while in a study of 
pediatric patients with SCD by Jain et al, 85% of patients received blood transfusion.(90,94). The 
difference of blood transfusion practices is variable in our country and there are no specific 
guidelines for blood transfusion in sickle cell disease, which can account for the difference in 
frequency of blood transfusion in different studies. 
In our study, cholilithiasis was documented in 6 patients (14%) as compared to 10% reported in a 
study by Tripathy et al in Orissa. (95). However, the difference could be due to that all patients 
in their study were screened for cholilithiasis with ultrasonography while in our study only 
symptomatic patients were screened. 
Other rarer complications documented in our patients included leg ulcers in 1.3% (n-3), seizure 
disorder in 0.8% (n-2) and stroke in 0.8% (n-2). These complications are considered rare in 
Indian patients with sickle cell disease and a prevalence of <1% for stroke and leg ulcers has 
been reported in various studies. (94,21).  In a study of Jamacian cohort of patients of sickle cell 
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disease, the cumulative incidence of seizures was reported as 2.2% , and in a study from 
Chhattisgarh India, seizure disorder was presenting symptom in 3.1% of patients.(36,96)  
Majority of patients (125, 54.5%) in our study presented with symptomatic anemia and the 
median hemoglobin for entire cohort was 8.7g/dl (range: 4-12.5g/dl) at the time of diagnosis. 130 
patients (56.5%) had leukocytosis (WBC count >10,000cells/mm3) at presentation. These 
findings are similar to study by Chandra et al, with hemoglobin at diagnosis of 8.3g/dl and 
leukocytosis was present in 41.8% of their patients. (90) The baseline hemoglobin F was 
available for 182 patients and median HbF was 19.5 %( 4.7-54%). This is higher as compared to 
data from western population (89) but is consistent with data from various Indian studies were 
HbF levels is known to be high. (94,97). 
During this study period, 27 patients of sickle cell disease underwent different surgical 
procedures. The orthopedic surgeries were most common surgeries performed, while other 
surgeries included cholecystectomy, splenectomy , lower segment caesarean section, mitral valve 
replacement and hepaticojejenusotomy. 88.8% (n-24) of surgeries were managed with simple 
perioperative while in 25.9% (n-6) exchange transfusion was done. Most of the surgeries were 
uneventful and postoperative complications was reported in 4 patients (14.8%) and included 
pneumonia/acute chest syndrome in one patient while other patients had complications unrelated 
to sickle cell disease (hematemesis in one patient, increased blood loss during surgery in one 
patient and urinary tract infection in one patient) .Perioperative ICU care was required in 4 
patients (14.8%) and there were no deaths reported. In a study by Sammak et al, retrospective 
analysis of 85 patients who underwent various surgical procedures were analyzed. In their study, 
21.2% patients received exchange transfusion while 24.7% patients received simple blood 
transfusion in the preoperative period. In about half of the patients (54.1%) no blood transfusion 
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was given. The postoperative complications in study were 14.1% which is similar to our study. 
However 50% of their postoperative complications were due to vaso occlusive crisis and 
incidence of ACS varied between 5-11% between various types of surgeries performed (98). The 
decreased incidence of sickle cell related complications in our study could be due more liberal 
use of preoperative transfusion in sickle cell patients. In a multicenter study by Vichinsky et al 
(99), 118 patients of sickle cell disease who underwent 138 orthopedic surgical procedures were 
analyzed to assess perioperative complications and outcome. In their study, 67% of patients had 
serious perioperative complication, while 17% experienced sickle cell related complications 
most commonly acute painful crises or acute chest syndrome. There were two deaths in 
perioperative period. This is higher as compared to our study and may be due to smaller number 
of procedures in our study and different patient characteristics as sickle cell disease is considered 
to be more severe in western patients as compared to Indian patient. 
Hydroxyurea was given in 222 patients (96.5%) at diagnosis while 8 patients (3.5%) where not 
started on hydroxyurea due to minimal symptoms at presentation. However, among these 8 
patients, two patients were started on hydroxyurea later due to increased symptoms while six 
patients continue to be on follow up without the use of hydroxyurea. The initial dose of 
hydroxyurea was 10mg/kg/day in most patients and was increased in case of inadequate response 
by treating clinician. The median dose of hyroxyurea was 15mg/kg/day (range: 10-35mg/kg/day) 
with majority of the patients (171 patients, 77.1%) receiving ≤15mg /kg/day. The data from 
western studies have used doses of upto 35mg/kg/d and in most the studies the starting dose is 
20-25mg/kg/day (83-86). However, in Indian patients, where baseline HbF is high and overall 
disease course is milder, the appropriate dose of hydroxyurea has not been well defined. In a 
study by Jain et al (100), low dose hydroxyurea (10mg/kg/day) was used in symptomatic 
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children with sickle cell disease and was found to be effective and safe.  In a study by Patel et al 
(101) from Eastern India, low dose hydroxyurea (10mg/kg/day) was used in adults and children 
with sickle cell disease and was shown to be effective in both adult and pediatric patients with 
sickle cell disease.  
The response to hydroxyurea therapy was assessed at six months and at last follow up. The 
median duration of follow up in our study was 36.25 months (range 6 -117months). 
There was significant improvement in clinical and laboratory parameters after the treatment with 
hydroxyurea. The frequency of painful crisis per year decreased from 3.4 to 0.9 (p<0.000) while 
blood transfusion requirement also decreased significantly (p<0.000). Out of ten patients who 
presented with transfusion dependent anemia at diagnosis, four patients became transfusion 
independent after hydroxyurea therapy other five patients had marked decrease in their 
transfusion requirement. One patient continued to have regular blood transfusion requirement 
and it was probably because large splenomegaly in that patient. The occurrence of acute chest 
syndrome decreased significantly from 14 episodes (6.3%) at diagnosis to 4 episodes (1.8%) at 
last follow (p=0.01). The role of hydroxyurea in ameliorating the clinical manifestations of sickle 
cell disease have been well documented in various studies from West including the large Multi 
Centre Study of Hydroxyurea in Sickle cell anemia (MSH), a double blind randomized 
controlled trail, which established the efficacy of hydroxyurea treatment in sickle cell disease. In 
this study by Charache et al (80), 152 patients were treated with hydroxyurea while 147 patients 
were given placebo. The was significant difference in annual rates of painful crisis (2.5 versus 
4.5), episodes of acute chest syndrome (25 versus 51) and decreased requirement for blood 
transfusion (48 versus 73) between the treatment group and control group. 
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In a study from India, Jain et al (100) treated 144 children with sickle cell disease with fixed 
dose of 10mg/kg/day of hydroxyurea for a median duration of 24 months. There was significant 
decrease in incidence of painful crises from 4.27 episodes/year to 0.15 episodes/year, acute chest 
syndrome (from 0.03 episodes/year to no episode during treatment), and blood transfusion 
requirement (0.77 units/year to 0.15 units/year). In another similar study by Singh et al (102), 24 
adult patients of sickle cell disease were prospectively treated with hydroxyurea for one year 
with a median dose of 22mg/kg/day. At the end of one year, there was significant decrease in 
annual frequency of painful crisis (3.63 to 1.67) and hospitalizations (4.75 to 2.25) suggesting 
the efficacy of hydroxyurea in adult Indian patients with sickle cell disease. Our study findings 
are similar to above studies. 
In our study, in addition to clinical improvement, the hematological parameters also showed 
significant improvement. The mean hemoglobin increased from 8.7±1.44 g/dl to 9.6±1.45 g/dl 
(p=0.000), while leucocyte count decreased from 11.71x103/mm3 (±5.5) to 9.0x103/ 
mm3(p0.000). The HbF value at baseline and after treatment was available in 34 patients and 
showed in increase from 18.3% (±6.6) to 25.9(±10.06) (p=0.000). These observations are similar 
to other studies which have documented a significant increase in hemoglobin and HbF after 
treatment with hydroxyurea in Indian patients.(101,102). 
Out of 230 patients, 222 patients who were treated with hydroxyurea urea and had at least six 
months follow up were included for response assessment. The response assessment was done 
after six months and at last follow up after initiation of hydroxyurea therapy. 
The response was defined in terms of complete response, partial response and no response (as 
defined above). After a median follow up of 36.25 months, 131 patients (57.4%) had complete 
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response, 86 patients (37.4%) while 5 patients (2.2%) did not show any response to hydroxyurea 
therapy. In a study by Patel et al from Orissa, India (101), 118 patients were prospectively 
observed for response to hydroxyurea for duration of two years. In their study, 92.2% of adult 
patients and 71.5% of pediatric patients were termed as responders (defined as at least 50% 
reduction in painful crisis). This is high as compared to our study, but in our study complete 
response was defined as complete resolution of presenting symptom while partial response was 
defined as 50% reduction, so taken together(complete and partial responders;94.8%), the 
response rates are similar. 
Hydroxyurea treatment was well tolerated in our cohort of patients with only 17 patients (7.6%) 
were documented to have adverse events. Most common side effects were hematological and 
include leucopenia in 10 patients (4.5%), thrombocytopenia in 4 patients and aplasia in one 
patient (0.9%). All events were mild and none required hospitalization or any other intervention 
except for dosage reduction of hydroxyurea. One patient who developed aplasia recovered 
counts after prolonged period was observation (about one year) and was asymptomatic on low 
dose of hydroxyurea (2.5mg/kg/day) at last follow up. These observations are similar to data 
from other Indian studies where mild hematological toxicity has been reported between 5-
7%.(100,102) However, it is significantly less as compared hematological toxicity as reported in 
MSH study where almost all patients developed some degree of neutropenia and required 
temporary treatment cessation or decrease in dose. The difference can be due to the high dose 
used in this study where the target was to achieve maximum tolerated dose (MTD) of 
35mg/kg/day. (80)  
On categorizing patients into homozygous sickle cell disease and sickle beta thalassemia, 148 
patients (64.4%) were having homozygous sickle cell disease were as 82 patients (35.6%) had 
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sickle beta thalassemia. There were no statistically significant differences in two groups with 
respect to median age first symptom (4 years in both) or gender distribution (male predominance 
in both groups). However median age at evaluation was lower in sickle beta thalassemia group as 
compared to homozygous sickle cell anemia (9 year versus 14years: p=0.03).There were no 
significant difference in frequency of painful episodes (83.1% versus 78%, p=0.37), anemia 
(66.2% versus 65.8%, p=1.0), avascular necrosis (15.5% versus 9.8%, p=0.33) or acute chest 
syndrome (8.1% versus 2.4%, p=0.1). However, splenomegaly was more commonly found in 
patients of sickle beta thalassemia as compared to homozygous sickle cell disease (73.1% versus 
37.1, p=0.000). There is limited data comparing the clinical features of homozygous sickle cell 
anemia with compound heterozygous sickle beta thalassemia. However, in a study of 21 patients 
of sickle beta thalassemia by Mukherjee et al, similar clinical features were observed in their 
patient cohort as in our study.(103). 
The comparison of laboratory parameters in these two groups of patient did not reveal significant 
difference with respect to mean hemoglobin, platelet count or HbF percentage at diagnosis. 
However, mean corpuscular volume, leucocyte count and reticulocyte percent were significantly 
low in sickle beta thalassemia as compared to homozygous sickle cell anemia. In addition 
median HbS percentage at diagnosis was higher in homozygous sickle as compared to sickle beta 
thalassemia. In our study, mean Hb for patients sickle beta thalassemia was 8.6 g/dl, mean 
corpuscular volume was 70fl , mean Hb F and HbS was 19.2% and 70.4% respectively. In a 
study of 21 patients of sickle beta thalassemia  by Mukherjee et al (103), mean hemoglobin at 
diagnosis was 7.8 g/dl which is lower than observed in our study, while mean MCV was 73fl 
which is similar to our study. The higher hemoglobin in our patient population could be due to 
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blood transfusions given before reporting to our hospital. The HbS percent and HbF percent 
observed in their study were similar to our study.  
On comparing the use and response of hydroxyurea in these two groups of sickle cell disease, 
there were no significant difference with respect to number of patients treated in each group 
(98% versus 93.9%, p=0.137), median dose of hydroxyurea used (15mg/kg/day in both group, 
p=1), or adverse events observed in these patients (8.2% versus 6.45,p=0.6). In addition, there 
was no significant difference in response to hydroxyurea treatment in these two groups as 
assessed at last follow up (complete respone:60.6% versus 55.8%, partial response:37.9% versus 
40.3% p=0.4). The above observations suggest that hydroxyurea can be as effective and safe in 
sickle beta thalassemia as in homozygous sickle cell disease. In a study by Dehury et al (104) 
from Orissa, India, 203 patients of sickle beta thalassemia were prospectively treated with 
hydroxyurea (at a fixed dose of 10mg/kg/day) for a median duration of two years. They reported 
marked improvement with respect to annual frequency of vaso-occlusive crisis (3.5 to 0), blood 
transfusion (1 to 0) and hospitalization (1 to 0) in both adult and pediatric patients as observed in 
our study. However, they did not compare the observation with homozygous sickle cell disease 
patients. 
A univariate logistic regression analysis of the common clinical and laboratory variables was 
done to detect predictors of complete response to treatment. This showed no significant 
association with age at presenting symptom (p=0.143), gender (p=0.112), homozygous sickle 
cell anemia versus sickle beta thalassemia (p=0.546), presenting symptom at diagnosis 
(p=0.154), leucocyte count (p=0.06), or platelet count (p=0.140) at diagnosis with the response 
status. However a significant association was observed with hemoglobin (p= 0.03), reticulocyte 
percent (p=0.03)and HbF percent (p=0.01) at diagnosis. It was observed that higher hemoglobin 
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and higher HbF percent at diagnosis are associated with higher rates of complete response at last 
follow up. A detailed literature search did not yield any studies  that have analyzed clinical 
variables for detecting response to hydroxyurea, however, in a study by Jain et al (100), higher 
baseline HbF was associated with significantly higher increase in HbF after hydroxyurea therapy  
resulting in better clinical response. In our study, in patients who had complete response at last 
follow up were having higher HbF levels as compared to patients who had partial or no response 
(p=0.004). This observation is similar to the study by Patel et al (101), who observed that, after 
hydroxyurea therapy,  HbF level was higher in responders as compared to non-responders. 
 
 
 
 
LIMITATIONS OF STUDY: 
1. Retrospective study: limited available data due to non-retrievable records. 
2. This cohort of patients may not be truly representative of general population because of the 
referral bias, since most of patients presenting to the department were from few select states 
(catchment area of hospital) and not representative of general population. 
3. Limited patient numbers and data available due to loss of follow up of patients 
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CONCLUSION: 
1. Bone pains and anemia are the most common manifestations, while stroke priapism and 
leg ulcers are rare in Indian patients of sickle cell disease. 
2. Homozygous sickle cell anemia and sickle beta thalassemia have similar clinical 
manifestations. 
3. Low dose hydroxyurea (up to 15mg/kg/day) is safe and efficacious in ameliorating the 
symptoms in both the patients of homozygous sickle cell anemia and sickle beta 
thalassemia. 
4. Surgical procedures can safely be performed in patients of sickle cell disease. 
5. Some patients of sickle cell disease, albeit very few, may not require treatment with 
hydroxyurea and can be followed with regular monitoring. 
6. Large prospective trials are required to form the guidelines for use of hydroxyurea in 
Indian patients with sickle cell disease addressing the issues of indications, dosage and 
monitoring. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
 
 
 
80 
 
Bibliography 
 
1. Wilson RE, Krishnamurti L, Kamat D. Management of sickle cell disease in primary care. 
Clin Pediatr (Phila). 2003 Dec;42(9):753–61.  
 
2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet Lond Engl. 2010 Dec     
11;376(9757):2018–31.  
 
3. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet Lond Engl. 2004 Oct 9;364(9442):1343–60.  
 
4. Pauling L, Itano HA. Sickle cell anemia a molecular disease. Science. 1949 Nov 
25;110(2865):543–8.  
 
5. Bunn HF. Pathogenesis and Treatment of Sickle Cell Disease. N Engl J Med. 1997 Sep 
11;337(11):762–9.  
 
6. Asakura T, Mattiello JA, Obata K, Asakura K, Reilly MP, Tomassini N, et al. Partially 
oxygenated sickled cells: sickle-shaped red cells found in circulating blood of patients with 
sickle cell disease. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12589–93.  
 
7. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle 
disease pathophysiology. Blood. 1991 Jan 15;77(2):214–37.  
 
 
 
81 
 
8. Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents 
most cells from sickling in vivo. Science. 1987 Jul 31;237(4814):500–6.  
 
9. Horiuchi K, Asakura T. Formation of light irreversibly sickled cells during deoxygenation-
oxygenation cycles. J Lab Clin Med. 1987 Nov;110(5):653–60.  
 
 
10. Odièvre M-H, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell 
disease. Indian J Med Res. 2011;134(4):532-537. 
11. Kuypers FA. Hemoglobin S Polymerization and Red Cell Membrane Changes. Hematol 
Oncol Clin North Am. 2014 Apr;28(2):155–79.  
 
12. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 
1997 Dec 1;100(11 Suppl):S83–6.  
 
13. Hebbel RP. Adhesion of sickle red cells to endothelium: myths and future directions. 
Transfus Clin Biol J Société Fr Transfus Sang. 2008 Mar;15(1-2):14–8.  
 
14. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated 
endothelial cells in sickle cell anemia. N Engl J Med. 1997 Nov 27;337(22):1584–90.  
 
15. Ballas SK. Sickle cell anemia with few painful crises is characterized by decreased red cell 
deformability and increased number of dense cells. Am J Hematol. 1991 Feb;36(2):122–30.  
 
 
 
82 
 
16. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: 
Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J 
Hematol. 2009 Sep;84(9):618–25.  
 
17. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the 
role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007 Jan;21(1):37–
47. 
  
18. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future 
promise. J Clin Invest. 2007 Apr;117(4):850–8.  
 
19. Lervolino LG, Baldin PEA, Picado SM, Calil KB, Viel AA, Campos LAF. Prevalence of 
sickle cell disease and sickle cell trait in national neonatal screening studies. Rev Bras Hematol E 
Hemoter. 2011;33(1):49–54.  
 
20. Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research 
priorities. Ann Trop Med Parasitol. 2007 Jan;101(1):3–14.  
21. R.Balgir. Epidemiology, Population Health Genetics and Phenotypic diversity of Sickle Cell 
Disease in India.The Internet Journal of Biological Anthropology. 2008,1:2 
 
22. Kate, S.L. and D.P. Lingojwar, Epidemiology of Sickle Cell Disorder in the State of 
Maharashtra. International Journal of Human Genetics, 2002.2(3): p. 161-167. 
 
 
 
83 
 
23. Kaur M, Dangi CBS, Singh M. An overview on sickle cell disease profile. Asian J Pharm 
Clin Res.2013.6(1):p2537 
 
24. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in 
sickle cell disease. Rates and risk factors. N Engl J Med. 1991 Jul 4;325(1):11–6.  
 
25. Aguilar C, Vichinsky E, Neumayr L. Bone and joint disease in sickle cell disease. Hematol 
Oncol Clin North Am. 2005 Oct;19(5):929–41 
 
26. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, et al. Daily 
assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008 Jan 15;148(2):94–
101.  
 
27. Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell 
disease. A study of the risk factors. Arch Intern Med. 1987 Jul;147(7):1231–4.  
 
28. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful 
crisis. Blood. 1992 Apr 15;79(8):2154–63. 
  
29. Embury SH, Dozy AM, Miller J, Davis JR, Kleman KM, Preisler H, et al. Concurrent sickle-
cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med. 1982 Feb 
4;306(5):270–4.  
 
 
 
84 
 
30. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. 
Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998 Jan 
1;91(1):288–94.  
 
31. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in 
sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 
9;330(23):1639–44.  
 
32. Abboud MR, Cure J, Granger S, Gallagher D, Hsu L, Wang W, et al. Magnetic resonance 
angiography in children with sickle cell disease and abnormal transcranial Doppler 
ultrasonography findings enrolled in the STOP study. Blood. 2004 Apr 1;103(7):2822–6.  
 
33. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, et al. The use of transcranial 
ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992 Feb 27;326(9):605–
10.  
 
34. Oyesiku NM, Barrow DL, Eckman JR, Tindall SC, Colohan AR. Intracranial aneurysms in 
sickle-cell anemia: clinical features and pathogenesis. J Neurosurg. 1991 Sep;75(3):356–63.  
 
35. Vichinsky EP, Neumayr LD, Gold JI, Weiner MW, Rule RR, Truran D, et al. 
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults 
with sickle cell anemia. JAMA. 2010 May 12;303(18):1823–31.  
 
 
 
85 
 
36. Ali SB, Reid M, Fraser R, MooSang M, Ali A. Seizures in the Jamaica cohort study of sickle 
cell disease. Br J Haematol. 2010 Nov;151(3):265–72.  
37. Siddiqui AK, Ahmed S. Pulmonary manifestations of sickle cell disease. Postgrad Med J. 
2003 Jul;79(933):384–90.  
 
38. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute 
chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of 
Sickle Cell Disease. Blood. 1994 Jul 15;84(2):643–9.  
39. Uong EC, Boyd JH, DeBaun MR. Daytime pulse oximeter measurements do not predict 
incidence of pain and acute chest syndrome episodes in sickle cell anemia. J Pediatr. 2006 
Nov;149(5):707–9.  
 
40. Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, et al. An official 
American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and 
management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014 
Mar 15;189(6):727–40.  
 
41. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 
2008 Nov 20;359(21):2254–65. 
  
42. Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S. Venous thromboembolism in 
adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013 
May;126(5):443–9.  
 
 
 
86 
 
43. Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and 
pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med. 2006 
Oct;119(10):897.e7–11.  
 
44. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and 
outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome 
Study Group. N Engl J Med. 2000 Jun 22;342(25):1855–65.  
 
45. Miller ST. How I treat acute chest syndrome in children with sickle cell disease. Blood. 2011 
May 19;117(20):5297–305.  
 
46. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, et al. Sickle cell disease 
as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991 Nov 21;325(21):1476–81.  
 
47. Hernigou P, Galacteros F, Bachir D, Goutallier D. Deformities of the hip in adults who have 
sickle-cell disease and had avascular necrosis in childhood. A natural history of fifty-two 
patients. J Bone Joint Surg Am. 1991 Jan;73(1):81–92.  
 
48. McAuley CF, Webb C, Makani J, Macharia A, Uyoga S, Opi DH, et al. High mortality from 
Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. 
Blood. 2010 Sep 9;116(10):1663–8.  
 
49. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis IJID 
Off Publ Int Soc Infect Dis. 2010 Jan;14(1):e2–12. 
 
 
87 
 
  
50. Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, et al. Incidence 
of invasive pneumococcal disease among individuals with sickle cell disease before and after the 
introduction of the pneumococcal conjugate vaccine. Clin Infect Dis Off Publ Infect Dis Soc 
Am. 2007 Jun 1;44(11):1428–33.  
 
51. Ward J, Smith AL. Hemophilus influenzae bacteremia in children with sickle cell disease. J 
Pediatr. 1976 Feb;88(2):261–3. 
  
52. Onwubalili JK. Sickle cell disease and infection. J Infect. 1983 Jul;7(1):2–20.  
 
53. Bennett OM, Namnyak SS. Bone and joint manifestations of sickle cell anaemia. J Bone 
Joint Surg Br. 1990 May;72(3):494–9.  
 
54. Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic 
sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985 
Aug;107(2):201–6.  
 
55. Piccin A, Smith OP, Murphy C, O’Marcaigh A, Corbally M, Mc Mahon C. Splenectomy in 
sickle cell anaemia: a cause of further crises? Br J Haematol. 2009 Apr;145(1):144–6.  
56. Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to 
parvovirus B19 infection in homozygous sickle-cell disease. Lancet Lond Engl. 2001 Nov 
24;358(9295):1779–80. 
  
 
 
88 
 
57. Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin North Am. 2005 
Oct;19(5):917–28.  
 
58. Adeyoju AB, Olujohungbe ABK, Morris J, Yardumian A, Bareford D, Akenova A, et al. 
Priapism in sickle-cell disease; incidence, risk factors and complications - an international 
multicentre study. BJU Int. 2002 Dec;90(9):898–902.  
 
59. Walker TM, Hambleton IR, Serjeant GR. Gallstones in sickle cell disease: observations from 
The Jamaican Cohort study. J Pediatr. 2000 Jan;136(1):80–5.  
 
60. Adam S, Jonassaint J, Kruger H, Kail M, Orringer EP, Eckman JR, et al. Surgical and 
obstetric outcomes in adults with sickle cell disease. Am J Med. 2008 Oct;121(10):916–21. 
  
61. Rhodes M, Akohoue SA, Shankar SM, Fleming I, Qi An A, Yu C, et al. Growth patterns in 
children with sickle cell anemia during puberty. Pediatr Blood Cancer. 2009 Oct;53(4):635–41.  
 
62. Singhal A, Gabay L, Serjeant GR. Testosterone deficiency and extreme retardation of 
puberty in homozygous sickle-cell disease. West Indian Med J. 1995 Mar;44(1):20–3.  
 
63. Cumming V, King L, Fraser R, Serjeant G, Reid M. Venous incompetence, poverty and 
lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell 
anaemia. Br J Haematol. 2008 Jul;142(1):119–25.  
 
 
 
89 
 
64. Fadugbagbe AO, Gurgel RQ, Mendonça CQ, Cipolotti R, dos Santos AM, Cuevas LE. 
Ocular manifestations of sickle cell disease. Ann Trop Paediatr. 2010;30(1):19–26.  
 
65. Sundaram N, Bennett M, Wilhelm J, Kim M-O, Atweh G, Devarajan P, et al. Biomarkers for 
early detection of sickle nephropathy. Am J Hematol. 2011 Jul;86(7):559–66.  
66. Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. 
ScientificWorldJournal. 2009;9:46–67.  
 
67. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal 
hemoglobin in sickle cell anemia. Blood. 2011 Jul 7;118(1):19–27.  
 
68. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012 
Aug;87(8):795–803.  
 
69. Sebastiani P, Solovieff N, Hartley SW, Milton JN, Riva A, Dworkis DA, et al. Genetic 
modifiers of the severity of sickle cell anemia identified through a genome-wide association 
study. Am J Hematol. 2010 Jan;85(1):29–35.  
 
70. Ryan K, Bain BJ, Worthington D, James J, Plews D, Mason A, et al. Significant 
haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol. 2010 
Apr;149(1):35–49.  
 
 
 
90 
 
71. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. 
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel 
members. JAMA. 2014 Sep 10;312(10):1033–48.  
 
72. Riddington C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal 
infection in children with sickle cell disease. Cochrane Database Syst Rev. 2002;(3):CD003427.  
 
73. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematol Educ Program 
Am Soc Hematol Am Soc Hematol Educ Program. 2013;2013:439–46.  
 
74. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first 
stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial 
Doppler ultrasonography. N Engl J Med. 1998 Jul 2;339(1):5–11.  
75. Swerdlow PS. Red cell exchange in sickle cell disease. Hematol Educ Program Am Soc 
Hematol Am Soc Hematol Educ Program. 2006;48–53.  
 
76. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell 
disease. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 
2013;2013:447–56.  
 
77. Preboth M. Management of pain in sickle cell disease. Am Fam Physician. 2000 Mar 
1;61(5):1544, 1549–50.  
 
 
 
91 
 
78. Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, et al. 
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for 
severe sickle cell phenotype. JAMA. 2014 Jul 2;312(1):48–56.  
 
79. Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, et al. Hydroxyurea for the 
treatment of sickle cell disease. Evid ReportTechnology Assess. 2008 Mar;(165):1–95.  
 
80. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of 
hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the 
Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995 May 
18;332(20):1317–22.  
 
81. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of 
hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 
years of treatment. JAMA. 2003 Apr 2;289(13):1645–51.  
 
82. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, et al. Hydroxyurea for 
treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996 Sep 15;88(6):1960–
4.  
83. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of 
hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001 Dec;139(6):790–6.  
 
 
 
92 
 
84. Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term 
hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 
2005 Oct 1;106(7):2269–75.  
 
85. Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, et al. From infancy 
to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. 
Medicine (Baltimore). 2014 Dec;93(28):e215.  
 
86. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide 
in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial 
(BABY HUG). Lancet Lond Engl. 2011 May 14;377(9778):1663–72.  
 
87. Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in 
sickle cell disease. Blood. 2014 Dec 18;124(26):3850–7; quiz 4004.  
 
88. Microsoft Word - haemoglobin_en.doc - haemoglobin.pdf [Internet]. [cited 2015 Oct 5]. 
Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf 
89. Neonato MG, Guilloud-Bataille M, Beauvais P, Bégué P, Belloy M, Benkerrou M, et al. 
Acute clinical events in 299 homozygous sickle cell patients living in France. French Study 
Group on Sickle Cell Disease. Eur J Haematol. 2000 Sep;65(3):155–64.  
 
90. Naval Chandra, Krishna Prasad A, Sudhir Reddy T, Shetty M, Subbalaxmi MVS, Raju YSN. 
Clinical profile of sickle cell syndromes: experience at a tertiary care centre in South India. J 
Clin Sci Res 2014;3:162-5 
 
 
93 
 
 
91. Meera.V, Gangadhar Belavadi, H.K.Govindiah, H.Sivaranjani. Clinical Profile of Sickle Cell 
Disease from a tertiary centre in Karnataka.2015 Jan;6(2):40-47 
 
92.nsth06_14.ac.gorakshakar.pdf [Internet]. [cited 2015 Sep 16]. Available from: 
http://www.rmrct.org/files_rmrc_web/centre’s_publications/nsth_06/nsth06_14.ac.gorakshakar.p
df 
 
93. Bainbridge R, Higgs DR, Maude GH, Serjeant GR. Clinical presentation of homozygous 
sickle cell disease. J Pediatr. 1985 Jun;106(6):881–5.  
 
94. Jain D, Bagul AS, Shah M, Sarathi V. Morbidity pattern in hospitalized under five children 
with sickle cell disease. Indian J Med Res. 2013 Sep;138(3):317–21.  
 
95. Tripathy D, Dash BP, Mohapatra BN, Kar BC. Cholelithiasis in sickle cell disease in India. J 
Assoc Physicians India. 1997 Apr;45(4):287–9.  
 
96. 2740_pdf.pdf [Internet]. [cited 2015 Oct 2]. Available from: 
http://www.ijpbs.net/cms/php/upload/2740_pdf.pdf 
 
97. Kar BC, Devi S. Clinical profile of sickle cell disease in Orissa. Indian J Pediatr. 1997 
Feb;64(1):73–7.  
 
 
 
94 
 
98. Al-Samak ZM, Al-Falaki MM, Pasha AA. Assessment of perioperative transfusion therapy 
and complications in sickle cell disease patients undergoing surgery. Middle East J Anaesthesiol. 
2008 Jun;19(5):983–95.  
 
99. Vichinsky EP, Neumayr LD, Haberkern C, Earles AN, Eckman J, Koshy M, et al. The 
perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National 
Sickle Cell Surgery Study Group. Am J Hematol. 1999 Nov;62(3):129–38.  
 
100. Jain DL, Apte M, Colah R, Sarathi V, Desai S, Gokhale A, et al. Efficacy of fixed low dose 
hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian 
Pediatr. 2013 Oct;50(10):929–33.  
101. Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC. Low dose hydroxyurea is 
effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle 
cell anemia patients from eastern India. Hemoglobin. 2012;36(5):409–20.  
 
102. Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Effective control of sickle cell disease 
with hydroxyurea therapy. Indian J Pharmacol. 2010 Feb;42(1):32–5.  
 
103. Mukherjee MB, Nadkarni AH, Gorakshakar AC, Ghosh K, Mohanty D, Colah RB. Clinical, 
hematologic and molecular variability of sickle cell-β thalassemia in western India. Indian J Hum 
Genet. 2010 Sep;16(3):154–8.  
 
 
 
95 
 
104. Dehury S, Purohit P, Patel S, Meher S, Kullu BK, Sahoo LK, et al. Low and fixed dose of 
hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) 
mutation. Pediatr Blood Cancer. 2015 Jun;62(6):1017–23.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix  
 
name hosp no age at dx age at dxgender Diagnosis-cmc Dx date of Dx family history presenting symptomAge at presenting symptomAge at first Txany other complicationany surgery doneAny exchange Tx givenomplications during surgeryTreatment givendose duration complications of treatmentany other complicationHb at Dx
at cmc outside 1-male 1-Homozygous SCDoutside . 1-yes 1- joint pain,3-AVN, 4-anemia 5-acute painful crises, 6-others. . abd -1, fever-21- y s 1yes . 1- hydroxyurea. . 1-leucopenia . .
. . 2-female 2-Compound B-scd. . 2-no 2- Transfusion dependence,1,4-7. 1,3-8.2,4-9. 1,3,4-10. 1,2-11. . 3-cholilithiasis, 4-infections2-no o . 2-nil . . 2- thrombocytopenia. .
. . . . . . . . . . 5-jaundice, 6-others, 7-3,4. 1,3-8.1,2-9 .2,5-10. -transfused. . . . 3-aplasia,4-Hyperpigmentation. .
CHUMKI PRADHAN 188250D 21 na 2 1 na 14/02/2008 2 8 16 20 nil 1 3 nil 1 15 nil nil 9.5
SHAMSHAD BEGUM 211678D 45 na 2 2 na 01/04/2008 2 7 45 45 nil 2 na na 1 20 2 1 nil 5.9
Golam Rabbani 040038D 6 4 1 1 1 06/06/2007 2 3 1 na nil 2 na na 1 15 7 nil constipation 8.5
Nasir  shaik 069442D 15 14 1 1 2 24/07/2007 2 7 14 14 1 2 na na 1 20 5 nil nil 6
Mathiyarasan 251164D 13 na 1 1 na 06/06/2008 2 7 3 12 1 2 na na 1 10 5 nil nil 7.6
Ramesh K 283477D 9 na 1 1 na 29/07/2008 2 1 1 9 6 2 na na 1 15 5 nil nil 5.4
Ayisa S 537891C 8 na 2 2 na 15/07/2005 2 1 5 5 nil 2 na na 1 20 9 nil nil 7.9
Sitaram Panika 305956D 9 7 1 1 1 10/09/2008 1 7 7 7 1 2 na na 1 15 5 nil nil 9.4
Mohammad Kaif 729074C 8 2 1 1 1 10/11/2005 2 1 1 na nil 2 na na 1 20 8 nil nil 7.7
Himanshu Manji 873740C 4 2 1 1 1 11/08/2006 2 1 2 na nil 2 na na 1 15 7 nil nil 8
Akash Kumar 356854D 9 9 1 1 1 21/11/2008 2 7 3 3 nil 2 na na 1 15 nil nil 8.5
Arti Singh 359287D 35 35 2 1 1 25/11/2008 2 1 25 na nil 2 na na 1 20 nil nil 9
Ramisetti ram narayan 653372C 7 7 1 1 1 14/06/2005 1 1 6 na nil 2 na na 1 20 nil nil 9.1
Prakash Kumar 189716D 16 3 1 1 1 18/02/2008 2 7 3 3 4 1 1 nil 1 15 nil nil 6.2
Hezekiya 191297D 4 3 1 2 1 27/02/2008 2 7 3 3 nil 2 na na 1 20 nil nil 7.1
Arthy 013724D 4 na 2 1 na 24/12/2008 2 4 1 1 nil 2 na na 1 25 4 nil nil 7.5
Mahtab Alam 446660D 4 4 1 1 1 20/04/2009 2 1 2 na nil 2 na na 1 20 nil nil 9.3
Rishu Yadav 453641D 5 3 1 1 1 01/05/2009 2 4 3 5 nil 2 na na 1 20 nil nil 8.3
Anil Mohan 470250D 25 15 1 1 1 29/05/2009 2 1 3 3 1 1 3 nil 1 10 nil nil 9.1
hema prabha 470986D 12 11 2 2 2 12/06/2008 2 7 11 11 nil 2 na na 1 10 nil nil 7.3
Susoritha 517921D 34 30 2 1 1 21/08/2009 2 7 5 6 6 2 na na 1 20 nil nil 8.8
santosh kumar 584281D 19 10 1 1 1 14/11/2009 2 7 3 6 4 1 3 nil 1 10 nil nil 8.8
Gondela  swathi 595387D 16 12 2 1 1 10/02/2010 2 1 12 15 3 2 na na 1 15 nil nil 9
Deepti Rekha 594265D 54 na 2 1 na 15/12/2009 1 4 54 na 3 2 na na 1 10 nil nil 7.3
Shamim MD 526962D 8 na 1 2 na 22/08/2009 2 7 8 na 1 2 na na 1 15 nil nil 8.1
Naveen P 562828c 9 5 1 2 1 07/01/2005 2 7 1 na 2 2 na na 1 10 nil nil 8.3
Mansi 401986D 4 2 2 2 2 17/02/2009 2 4 2 2 nil 2 na na 1 15 nil nil 10.5
Suman Maity 632161D 11 5 1 2 1 10/02/2010 2 7 5 5 nil 2 na na 1 15 nil nil 7.1
Meyyalagan 637199D 7 6 1 1 1 12/02/2010 2 7 5 5 nil 2 na na 1 15 nil nil 8
Siva kumar 543180D 17 10 1 1 1 21/09/2009 2 1 10 15 nil 2 na na 1 10 1 nil 9.5
Akanksha Sahu 641695D 21 2 2 1 1 21/02/2010 2 7 2 2 3 1 3 nil 1 10 nil nil 6.7
Mukilan B 672568C 1 na 1 2 na 22/07/2005 1 10 1 1 4 2 na na 1 10 nil nil 7.1
Santanu Roy 720432D 5 4 1 2 1 06/08/2010 2 4 4 4 nil 2 na na 1 10 nil nil 9.6
Jasmin Rexna khora 751448D 28 5 2 1 1 18/08/2010 2 10 5 14 3 1 3 na 1 15 nil nil 9.5
Atanu Roy 756071D 1 na 1 2 na 09/08/2010 2 4 1 1 nil 2 na na 1 15 nil nil 7.9
philip Mathew 772923D 13 12 1 1 1 02/09/2010 2 7 2 2 7 1 3 na 1 10 nil nil 7.5
Murali M 771155D 16 na 1 2 na 01/09/2010 2 1 12 na 1 2 na na 1 10 nil nil 8.9
Sesi bhushan k 766480D 21 12 1 2 1 23/08/2010 2 1 3 3 1 2 na na 1 10 nil nil 10.2
Vikash Kurrey 812563D 28 5 1 1 1 28/10/2010 1 11 5 5 nil 2 na na 1 10 nil nil 8.6
Sarathi K 798979D 7 na 1 1 na 04/12/2010 2 4 1 1 4 2 na na 1 10 nil nil 6.9
Balaji Naik 749257D 22 18 1 2 1 24/08/2010 2 7 15 15 nil 1 3 nil 1 20 nil nil 11.3
gunasrija 867176D 1 1 2 1 1 11/01/2011 2 1 1 na nil 2 na na 1 10 nil nil 9.8
Sheikh Sultan 843311D 24 na 1 1 na 04/01/2011 2 1 3 na nil 2 na na 1 10 nil nil 10.3
Sohel hussain 925894D 20 na 1 1 na 10/05/2011 2 4 4 4 3 2 na na 1 10 nil nil 6.9
mohammad azad K 935488D 7 6 1 2 1 21/05/2011 2 1 6 na nil 2 na na 1 10 nil nil 7.1
Prafulla Sahu 976624D 24 3 1 1 1 29/06/2011 2 8 3 22 nil 1 3 nil 1 20 nil nil 9.4
Hari Prasanth 003566f 6 5 1 2 1 29/08/2011 2 4 5 5 nil 2 na na 1 15 nil nil 8.4
Pawan Kumar 000503F 5 3 1 2 1 03/08/2011 1 7 3 3 nil 2 na na 1 10 nil nil 9.8
rahamatullah 985608D 29 17 1 2 1 06/09/2011 1 1 17 na nil 2 na na 1 20 nil nil 8.9
Bharat J 038970F 3 3 1 2 1 20/08/2011 2 7 3 na nil 2 na na 1 15 nil nil 6.8
Saroj Devi 037746F 24 10 2 1 1 21/09/2011 2 8 10 na 6 1 3 nil 1 10 nil nil 9.6
Satish Kumar 017115F 51 35 1 1 1 05/10/2011 2 1 5 50 nil 2 na na 1 10 nil nil 10.2
Ramya C 957830D 24 7 2 1 1 03/06/2011 2 1 6 6 4 2 na na 1 10 nil nil 8.1
Basanti gadi Shyam 084348F 25 15 2 2 1 09/12/2011 1 1 15 20 nil 2 na na 1 10 nil nil 10
Mirnalini 101191F 1 1 2 1 1 20/12/2011 2 4 1 na nil 2 na na 1 10 nil nil 8.1
Baidnath Malakar 894599D 14 12 1 1 1 01/03/2011 2 1 5 10 nil 2 na na 1 20 nil nil 8
snigdha Das 840709D 12 3 2 1 1 07/12/2011 1 1 3 3 nil 2 na na 1 15 nil nil 9.5
Ram Bharat Singh 476079D 32 22 1 2 1 16/06/2009 2 9 18 18 3 2 na na 1 15 nil nil 8.3
Esther Hannan G 003393F 13 5 2 2 1 19/08/2011 1 7 5 7 nil 2 na na 1 12 nil nil 9.6
degala Prasad 042086F 9 5 1 1 2 27/09/2011 2 4 5 5 1 2 na na 1 15 nil nil 8.3
Mohammad Uzair 011062F 4 4 1 2 1 28/10/2011 2 7 4 4 1 2 na na 1 15 nil nil 8.2
Nishant Chandra 076180F 6 4 1 1 1 15/11/2011 2 7 4 4 nil 2 na na 1 15 nil nil 10.3
Nikhil Khora 084343f 6 5 1 1 1 25/11/2011 2 7 4 4 4 2 na na 1 20 nil nil 7.3
Mamidi Shanmukha 083243F 16 15 1 1 1 09/12/2011 2 4 4 7 6 2 na na 1 15 nil nil 7.9
Priya Nair 051989F 22 12 2 1 1 12/01/2012 2 11 12 12 nil 2 na na 1 15 nil nil 9.9
Samarat kumar 105314F 4 1 1 1 1 13/01/2012 2 4 1 3 nil 2 na na 1 30 nil nil 6.2
Sankar Naik 132496F 22 12 1 2 1 27/02/2012 2 1 12 12 nil 2 na na 1 10 nil nil 9.8
Baibhab Patra 146404F 1 1 1 1 1 25/02/2012 2 1 1 na nil 2 na na 1 35 nil nil 7.4
Nisha Kumari 170577F 9 7 2 1 1 10/04/2012 1 7 3 3 nil 2 na na 1 15 nil nil 8.2
Jawaharlal M 180358F 24 20 1 1 1 19/04/2012 2 1 15 15 1 2 na na 1 15 nil nil 8.9
Pankaj Singh 181529F 28 3 1 2 1 22/05/2012 2 7 3 5 7 2 na na 1 15 nil nil 8.3
Anitesh Shit 270250F 11 1 1 2 1 14/08/2012 2 1 3 na nil 2 na na 1 20 2 nil 9.6
Chaitanya Naik 272840F 6 4 1 2 1 28/08/2012 2 7 2 2 nil 2 na na 1 15 nil nil 7.8
Rashmi Rose 272381F 37 30 2 2 1 04/09/2012 2 7 30 30 6 2 na na 1 10 nil nil 8
Uthra Kumari 828413A 26 20 2 1 1 17/07/2012 1 1 12 12 nil 2 na na 1 15 nil nil 7.1
Sk Niyamat 317565F 18 na 1 1 na 23/11/2012 2 7 6 6 nil 2 na na 1 15 nil nil 9.3
Kundan Mukhi 290724F 35 20 1 1 1 09/10/2012 2 1 12 12 3 1 1 nil 1 10 nil nil 8
Megha Mahpatra 319938F 6 na 2 2 na 11/10/2012 2 1 6 6 1 2 na na 1 15 nil nil 7
Venkat B 325328F 5 4 1 1 1 02/11/2012 2 7 4 5 nil 2 na na 2 na na na 8.8
Surya Kanth 330502F 5 2 1 1 1 16/11/2012 2 7 2 2 nil 2 na na 1 15 nil nil 9.7
Supriya G 324118F 12 3 2 1 1 25/10/2012 2 4 1 1 nil 2 na na 1 15 nil nil 8.4
Lingam Sonu 343284F 16 16 1 1 1 18/12/2012 2 1 16 na nil 2 na na 2 na nil nil 11.4
Juhi Urshala 141377F 5 4 2 1 1 02/03/2012 2 1 3 3 nil 2 na na 1 10 nil nil 11.3
Sanjay 184231F 2 2 1 2 1 18/04/2012 2 4 2 2 nil 2 na na 1 15 nil nil 8.5
Abhishek P 195777F 6 na 1 1 na 16/05/2012 2 7 3 3 nil 2 na na 1 15 nil nil 10.9
Palak Kumari 202784F 9 7 2 2 1 01/06/2012 2 7 5 5 nil 2 na na 1 20 nil nil 8
Rounak Kumar 217489F 3 3 1 1 1 03/07/2012 2 4 3 3 nil 2 na na 1 15 nil nil 9.4
Mohammad Nadim 284076F 4 4 1 2 2 14/09/2012 2 4 4 4 nil 2 na na 1 15 nil nil 8
Vijayasree 283390F 4 4 2 1 1 14/09/2012 2 1 4 4 1 2 na na 1 10 nil nil 10.3
jogeshwar bhakat 233760F 14 5 1 2 1 26/06/2012 2 4 5 4 1 2 na na 1 10 1 nil 7.4
Arbaz Khan 302193F 10 7 1 2 2 05/10/2012 2 7 7 7 1 1 3 na 1 20 nil nil 6.3
Ram roshan 320344F 4 3 1 1 1 26/10/2012 2 7 3 3 nil 2 na na 1 10 nil nil 9.4
Pratibha 328055F 9 7 1 2 1 26/10/2012 2 7 6 6 1 2 na na 1 10 nil nil 8.2
Badre Alam 879287D 28 na 1 1 na 05/02/2011 2 3 5 12 6 1 1 nil 1 20 nil nil 11.3
Swarna  Mahnt 398956F 13 11 2 1 1 01/02/2013 2 4 7 7 6 2 na na 1 20 nil nil 8.9
Subash Karmakar 936077D 21 12 1 1 1 03/05/2011 2 1 10 na nil 2 na na 1 25 nil nil 9.6
Tarani 400201F 7 5 2 1 1 15/02/2013 2 7 2 2 nil 2 na na 1 10 nil nil 8
Rahul raj Baraik 407825F 12 4 1 1 1 14/02/2013 2 4 4 4 3 2 na na 1 10 nil nail hyperpigmentation8
Ayush Kumar 414352F 12 3 1 2 2 01/03/2013 2 7 3 10 nil 1 1 nil 2 na nil nil 6.2
Joy Nayek 391249F 10 2 1 1 1 26/02/2013 2 1 2 na nil 2 na na 1 10 nil nil 8.5
Gopika 420804F 4 3 2 2 1 09/04/2013 2 1 3 na nil 2 na na 1 15 nil nil 10.7
Varsha Chauhan 427663F 5 4 2 2 1 19/03/2013 2 7 3 3 1 2 na na 1 20 nil nil 7.3
Vasu pali 426624F 12 7 1 2 1 26/03/2013 2 7 7 7 nil 2 na na 1 10 nil nil 11.2
Srilatha 411243F 13 4 2 2 1 02/04/2013 1 7 4 4 nil 2 na na 1 10 nil nil 9.9
Dewashish kumar 491184F 11 3 1 1 1 28/05/2013 2 11 3 3 nil 2 na na 1 15 1 nil 8.6
Adarsh Kumar 449837F 3 3 1 2 1 03/05/2013 2 4 3 2 nil 2 na na 2 na na na 4
Sarwan Kumar 608561F 34 30 1 1 1 25/06/2013 2 1 24 24 nil 2 na na 1 25 nil nil 6.8
Rathina Vel 496877f 14 na 1 1 na 10/06/2013 2 4 12 12 nil 2 na na 1 15 nil nil 6
Akhila S 616502F 10 6 2 1 1 19/07/2013 2 1 6 na nil 2 na na 1 15 nil nil 8.6
Mahesh Nimala 636246F 18 12 1 1 1 16/08/2013 2 1 10 na nil 2 na na 1 15 nil nil 11.4
Ravichandran 617678F 20 na 1 2 na 04/07/2013 2 1 16 na 1 2 na na 1 10 nil nil 8.4
Kamal Hussain 650657C 11 7 1 1 1 07/06/2005 2 7 2 1 nil 2 na na 1 10 nil nil 10.6
Sidhardha 635661F 5 5 1 2 1 23/08/2013 2 4 3 3 nil 2 na na 1 20 nil nil 9.1
Aman Kumar 660512F 7 4 1 1 1 27/08/2013 2 4 4 na 5 2 na na 1 20 nil nil 8
Roushani Kumari 660300F 9 9 2 2 1 10/09/2013 2 1 3 na 1 2 na na 1 10 nil nil 9.8
Debasis Gouda 652288F 7 4 1 1 2 13/09/2013 1 1 4 na 1 2 na na 1 15 nil nil 9.6
Nilandri Gouda 652286F 10 6 2 1 2 13/09/2013 1 1 6 7 nil 2 na na 1 15 nil nil 10.2
Murali N 145581F 22 na 1 1 na 29/03/2012 2 1 1 10 nil 2 na na 1 25 nil nil 9.4
Rabiul Mondal 683802F 28 na 1 1 na 24/09/2013 2 7 18 24 5 2 na na 1 10 nil nil 8.3
Smriti verma 660788F 32 6 2 1 1 14/09/2013 2 8 6 12 4 1 3 nil 1 15 nil nil 9.1
Kanak Prakash 638400F 14 6 1 1 1 08/10/2013 2 7 6 6 5 2 na na 1 15 nil nil 8.4
Rohith K 685214F 5 2 1 1 1 11/10/2013 2 1 2 3 nil 2 na na 1 10 nil nil 9.2
Koruvada Jyoti 722522f 26 26 2 1 1 26/11/2013 2 1 20 22 nil 2 na na 1 20 nil nil 7.8
Nigar Tirkey 729710F 36 36 2 1 1 10/12/2013 2 4 30 na 5 2 na na 1 10 nil nil 9.5
Bushra Arsh 768016F 4 2 2 1 1 20/12/2013 1 1 2 na nil 2 na na 1 15 nil nil 9.7
Hammad Nasim 768015F 9 6 1 1 1 20/12/2013 1 1 1 na nil 2 na na 1 15 nil nil 8.6
Avimanu Kumar 445268F 14 10 1 1 1 09/04/2013 2 1 3 7 nil 2 na na 1 15 1 nil 10.8
Brinda 479062F 5 3 2 2 1 04/06/2013 2 4 2 2 nil 2 na na 1 15 nil nil 7.9
Abhey Pandey 622046F 13 13 1 2 2 26/07/2013 2 1 13 na nil 2 na na 1 10 nil nil 9.8
Kalam Ansari 670766F 7 6 1 2 2 01/10/2013 2 7 3 3 nil 2 na na 1 15 nil nil 9.8
Sambasiva Rao 656969F 24 14 1 1 1 10/09/2013 2 8 14 14 nil 1 3 nil 1 15 2 nil 10.9
Arpit Singh 693867F 7 7 1 1 1 29/10/2013 2 7 4 4 nil 2 na na 1 10 nil nil 8.3
deepshikha Tirkey 711168C 12 12 2 1 1 10/10/2005 2 7 5 5 nil 2 na na 1 25 nil nil 6.4
Sourav Kumar 810004C 3 3 1 1 1 20/04/2006 2 1 2 3 1 2 na na 1 20 nil nil 10.2
indrajeet patra 919991c 24 12 1 1 1 30/10/2006 2 7 12 12 1 2 na na 1 20 nil nil 9.6
tarun Shankar 980186C 19 na 1 1 na 16/02/2007 1 7 1 3 nil 2 na na 1 20 nil nil 10.6
lingam sujata 816973C 19 10 2 1 1 05/05/2006 2 7 10 10 1 1 3 nil 1 20 nil nil 7
Ranjeeth 750810C 7 na 1 1 na 27/12/2005 2 1 2 5 9 2 na na 1 15 nil nil 9.4
Chandini D 065934D 8 8 2 1 1 17/07/2011 1 7 4 5 2 2 na na 1 15 nil nil 6.8
Santosh Pradhan 188241D 19 12 1 1 1 19/02/2008 1 1 12 12 nil 2 na na 1 10 nil nil 9.5
Mamta Yadav 179256D 29 20 2 1 1 22/02/2008 2 1 20 20 3 1 2 na 1 10 2 nil 10.2
Nadeem 193204D 3 na 1 1 na 26/02/2008 2 7 3 3 2 2 na na 1 15 nil nil 10.9
Devashish Goswami 291404B 47 34 1 2 1 20/05/2008 2 1 15 na 3 2 na na 2 na na na 10.2
Upasna Poorna 898415B 26 5 2 1 1 20/07/2008 2 7 5 12 nil 2 na na 1 15 4 nil 10.4
Moureshwara 096525D 4 4 1 1 1 01/09/2007 2 1 3 na nil 2 na na 1 20 nil nil 7.8
Rishana 248992D 7 3 2 1 2 30/05/2008 2 4 3 3 2 2 na na 1 15 nil nil 10.7
sujan baraik 333754D 19 na 1 1 na 13/10/2008 2 4 15 5 3 1 2 na 1 10 nil nil 9.9
Mohammad Rafik 364243D 28 22 2 1 1 05/11/2008 2 1 3 15 3 1 3 nil 1 10 nil nil 8.6
Kanishk 201280D 4 4 1 2 1 11/04/2008 2 4 3 3 nil 2 na na 1 15 nil nil 8.5
priyanshu 201117D 8 1 2 1 1 12/03/2008 2 9 1 1 1 2 na na 1 15 nil nil 8.1
Simran Taj 274432D 7 7 2 1 2 18/07/2008 2 4 1 2 2 2 na na 1 15 nil nil 9.1
Mohammad Furqan 277711d 5 4 2 2 2 21/07/2008 2 4 4 4 1 2 na na 1 15 nil nil 8.2
Akash Gorai 280801D 9 na 1 2 na 25/07/2008 2 4 7 8 2 2 na na 2 na na na 9
Sandeep 322290D 4 2 1 2 2 24/09/2008 2 4 2 2 2 2 na na 1 15 nil nil 7.1
manik ghashi 321588d 26 23 1 1 1 30/09/2008 2 1 3 25 nil 2 na na 1 10 nil nil 11.4
sahil sahu 381947d 9 3 1 2 2 09/01/2009 2 7 2 3 1 2 na na 1 15 nil nil 8.9
surya durga prasad 384636D 19 3 1 2 2 05/01/2009 2 1 3 18 5 2 na na 1 10 nil nil 11.9
lokesh kumar 304843d 23 18 1 1 1 30/08/2008 2 8 12 22 4 1 1 na 1 10 nil nil 11.5
draupadi Patra 461111D 23 7 2 1 1 15/05/2009 2 4 7 7 nil 2 na na 1 15 nil nil 5.5
Swagatika bhuyan 477326d 14 nd 2 1 nd 09/06/2009 2 8 10 10 nil 2 na na 1 10 nil nil 9.5
kamal uddin ansari 489966d 22 21 1 1 1 29/06/2009 2 8 3 21 10 2 na na 1 10 nil nil 7.4
kala rani 519686d 27 24 2 1 1 18/08/2009 2 1 3 7 5 1 3 na 1 20 nil nil 9.6
neha khatoon 506030d 10 9 2 1 1 31/07/2009 2 4 9 6 nil 2 na na 1 15 nil nil 7.6
Srikanth 396787D 9 5 1 2 1 06/02/2009 2 9 5 4 5 1 3 nil 1 15 nil nil 9.8
kumar Ayush 652379C 2 na 1 2 na 11/06/2005 2 4 1 na 5 2 na na 2 na nil nil 9.4
Kinche giridhar 425708d 8 7 1 1 1 24/03/2009 1 4 7 7 2 2 na na 1 15 nil nil 6.5
janardan kumar 633273d 18 9 1 1 1 06/04/2010 2 1 9 15 2 2 na na 1 20 nil nil 9.9
samaresh maity 636432d 8 3 1 2 2 16/02/2010 1 1 3 na nil 2 na na 1 12 nil nil 7.8
priyanka kumari 626818c 24 5 2 1 1 19/04/2005 2 1 3 15 4 1 3 nil 1 15 1 nil 10.7
lavanya N 641794D 14 nd 2 1 nd 16/04/2010 2 1 3 5 2 na na 1 15 nil nil 7.2
Anup kumar sahu 645331d 13 na 1 2 na 26/02/2010 2 1 3 na 6 2 na na 1 15 nil nil 9.7
kavitha S 681073d 31 nd 2 1 nd 20/04/2010 1 1 nd 25 nil 1 3 nil 1 20 nil nil 9.9
Archana kumari 636836d 17 15 2 1 1 09/03/2010 2 1 15 na nil 2 na na 1 15 nil nil 10.6
Dhash Chourey 613785D 4 1 1 2 1 03/08/2010 1 7 1 1 nil 2 na na 1 15 nil nil 7.7
Rathi D 752782D 22 6 2 1 1 10/08/2010 1 1 6 15 2 2 na na 1 15 nil nil 9.3
Sridhar 807073D 14 9 1 1 1 15/10/2010 2 1 9 na nil 2 na na 1 15 nil nil 9.2
Ahmed Aslam 811759D 29 21 1 2 2 22/10/2010 1 1 3 na nil 2 na na 1 15 nil nil 9
Bharati kumari 814371D 17 14 2 1 1 26/11/2010 2 1 14 10 8 1 3 na 1 15 nil nil 9.4
jahangir Alam 848257D 24 13 1 1 1 11/01/2011 1 1 13 13 nil 2 na na 1 10 nil nil 11.6
Gadi Ram sai prasad 700391D 9 1 1 2 2 20/05/2010 2 7 1 1 nil 2 na na 1 30 nil nil 7.7
Tapas Mohanty 792234D 28 15 1 2 2 23/09/2010 2 7 7 14 nil 2 na na 1 10 nil nil 8.9
Mangel Patel 848222D 20 10 1 2 1 11/01/2011 2 7 3 15 nil 2 na na 1 15 nil nil 9.1
maryam moosa 854556d 22 19 2 1 1 14/01/2011 1 1 19 na nil 2 na na 1 15 4 nil 9.5
Krishnaveni 863070d 37 nd 2 1 nd 13/01/2011 1 1 3 na 3 1 3 wound infection2 na na na 10.1
Raj kumar M 854913D 16 na 1 2 na 01/02/2011 2 1 13 na 10 2 na na 1 10 1 nil 9.7
Pratikshya patel 906604d 11 5 2 1 1 29/03/2011 2 8 6 na nil 1 3 nil 1 15 nil nil 9.6
Anas Ansari 821540D 1 na 1 2 na 03/04/2011 2 4 1 1 2 2 na na 1 20 nil nil 7.9
Rohan tanty 893441D 17 na 1 2 na 09/04/2011 2 1 3 10 5 2 na na 1 15 nil nil 11
Lakshmi kumari 944730D 11 9 2 1 1 18/05/2011 2 4 7 7 1 2 na na 1 15 nil nil 9.8
urvashi kumari 960662D 20 19 2 1 1 01/07/2011 2 4 3 19 3 1 3 nil 1 12.5 nil nil 4.8
Mitali Singh 988760C 3 na 2 1 na 24/08/2011 2 1 2 3 1 2 na na 1 15 nil nil 7.3
Samiruddin ansari 034065F 30 20 1 2 1 20/09/2011 2 1 20 20 5 2 na na 1 10 nil nil 9.3
Prince kumar 092654f 18 6 1 2 1 16/12/2011 2 1 5 5 nil 2 na na 1 15 nil nil 9.5
Jithenra 940028D 1 1 1 1 1 10/05/2011 2 4 1 1 2 2 na na 1 15 nil nil 6.9
mitlesh kumar 086795D 29 nd 1 1 nd 21/08/2007 2 1 3 20 nil 2 na na 1 15 1 nil 10.3
Subrata das 964237D 28 na 1 2 na 06/09/2011 2 4 15 27 1 2 na na 1 10 nil nil 7.1
nidhi mandavi 052038F 16 nd 2 2 nd 15/02/2012 2 9 7 7 8 2 na na 1 20 nil nil 5.8
Aryan lima 084121F 8 3 1 1 1 25/11/2011 2 7 1 2 nil 2 na na 1 15 1 nil 8.2
Bollam viswahith 064379F 2 2 1 1 1 06/12/2011 2 4 1 1 nil 2 na na 1 15 nil nil 11.9
Rabindra Shasni 157605F 20 9 1 1 1 12/03/2012 2 7 9 20 nil 2 na na 1 10 nil nil 7.8
rajasri M 263420F 4 3 2 2 2 31/08/2012 2 1 3 na nil 2 na na 1 12 nil nil 8.6
suraj koiri 292289F 13 na 1 2 na 06/09/2012 2 6 2 13 6 2 na na 1 15 nil nil 6.3
Nisha Kumari 307193F 15 11 2 2 2 12/10/2012 2 7 4 8 nil 2 na na 1 25 1 nil 8.6
bikash patel 186068F 21 1 1 1 1 27/04/2012 1 1 3 6 nil 2 na na 1 15 nil nil 8.2
rhadeshayam 342195F 17 6 1 1 1 20/11/2012 1 7 6 6 9 2 na na 1 20 nil nil 9.8
Shakeel ahmed 353456F 24 16 1 1 1 24/11/2012 1 1 16 16 nil 1 1 nil 1 15 nil nil 10.8
dilip kumar sahu 123321F 47 3 1 1 1 24/01/2012 2 1 2 25 6 1 na na 1 15 3 nil 6.2
Alka Shewta 217161F 29 20 2 2 1 08/06/2012 1 7 19 20 nil 2 na na 1 10 nil nil 8.9
Sovika Das 164092F 12 na 1 2 na 08/06/2012 2 1 12 na nil 1 3 nil 1 10 nil nil 10
ritika Kumari 248905F 8 6 2 2 2 19/07/2012 2 7 5 5 nil 2 na na 1 15 nil nil 9.9
jaharul Sarkar 285586F 24 14 1 1 2 04/09/2012 2 1 14 14 2 2 na na 1 20 2 nil 7.8
javed Akhter 361222F 17 na 1 2 na 18/12/2012 2 4 16 16 nil 2 na na 1 10 nil nil 9.7
Siddhardha 293939F 6 3 1 1 2 16/10/2012 2 7 3 3 2 2 na na 1 20 nil nil 10.9
golluri nandini 293932F 15 4 2 1 2 16/10/2012 2 4 4 4 nil 2 na na 1 20 nil nil 10.4
Anshul L 383511F 9 2 1 2 1 08/01/2013 2 1 2 2 2 2 na na 1 20 nil nil 8.8
Hemanth Naik 410972F 5 4 1 1 1 12/02/2013 2 4 2 2 nil 2 na na 1 15 nil nil 8.4
Gautam 388113F 9 6 1 1 na 11/01/2013 2 7 3 6 nil 2 na na 1 20 nil nil 9.2
Dhanya S 973919C 4 na 2 1 na 07/02/2007 2 4 4 4 2 2 na na 1 10 nil nil 10
aman nair 649506c 8 na 1 2 n 25/10/2005 2 4 4 8 5 2 na na 1 15 nil nil 7.1
Prabu C 758508C 22 20 1 1 1 10/01/2006 2 1 12 22 5 2 na na 1 25 nil nil 9.9
Prakash kumar nayak 790685C 28 28 1 1 na 14/03/2006 2 1 3 na nil 2 na na 1 10 nil nil 12.5
Sumeet kumar 724311C 13 9 1 1 1 10/10/2005 2 9 1 1 nil 2 na na 1 15 nil nil 8.2
samartha das 951351c 5 2 1 2 2 22/12/2006 2 1 5 na nil 2 na na 1 15 nil nil 10.1
Pethiraj 954969C 30 na 1 1 na 11/01/2007 2 1 30 na 5 2 na na 1 20 nil nil 9.2
Thenmozhi 083969D 12 11 2 1 1 17/08/2007 2 1 5 11 nil 2 na na 1 10 nil nil 8.5
Naveen Raja 083842D 5 na 1 1 na 27/11/2007 1 1 5 na nil 2 na na 1 15 nil nil 9.3
urmila devi 102874D 30 na 2 2 na 18/09/2007 2 9 21 30 nil 2 na na 1 10 nil nil 8.8
deepali 609413C 10 3 2 1 1 15/03/2005 1 1 3 na nil 2 na na 1 10 nil nil 8.4
Jiwan kumar 733038C 21 na 1 2 na 22/11/2005 2 1 3 3 5 2 na na 1 12 nil nil 9.7
Kalyani 609411C 6 1 2 1 1 15/03/2005 1 9 1 1 2 1 3 nil 1 20 nil nil 8.2
WBC at DxPlt Retic at DxMCV-Dx creat at dxHb-F at Dx HbS at DxHb-6m mcv-6m creat-6m Tx-last 6m Painful crises-6mPainful Crises Frequency-LFUVc crises frquency-LFUACS date of last follow upC mplianceResponse at last f/u
. . . . . (%) (%) . . . . . (/yr) . . . 1-good .
. . . . . . . . . . . . . . . . 2-Poor compliance/f.u.
. . . . . . . . . . . . . . . . . .
11200 363000 4.2 75.2 0.6 18.3 76.7 11.3 na nil nil nil nil nil 18/02/2014 1 1
8800 413000 10.99 61.5 1 4.7 86.6 6.7 0.9 2 nil nil nil nil 14/03/2014 1 2
14200 302000 12.48 84 0.4 12.2 82.2 9.5 88.5 0.4 nil nil 1 nil nil 04/06/2014 1 1
na na na na 0.5 18.3 na 9.9 na nil nil nil nil nil 06/06/2012 1 1
13700 518000 8 77.4 0.5 11.7 83 6.7 na nil 1 1 nil nil 16/05/2014 1 2
12400 205000 20.18 81.6 0.5 23.3 71 10.3 na nil nil 1 nil 1 26/12/2014 1 2
15400 699000 8.2 70 na 6.1 81.1 9.6 na nil 1 3 nil nil 22/08/2014 1 2
16900 426000 4 64 0.5 10.6 61 8.8 62.5 na nil nil 1 1 nil 26/09/2014 1 2
15700 242000 14.75 87 0.4 20.7 73.2 8.2 na nil 1 1 1 nil 21/04/2014 1 2
24800 112000 13.48 89.3 0.5 11.4 82.4 8.5 105.6 na nil nil 1 nil nil 27/04/2010 1 2
10500 459000 6.25 81.4 0.5 16.6 77.3 10.1 na nil 1 1 nil nil 25/09/2014 1 2
11700 186000 7.2 95 0.8 18.3 76.5 9 na nil nil nil nil nil 18/08/2014 1 1
8100 266000 6.4 96 0.6 29.7 66 10.8 na nil nil 0.25 nil nil 28/03/2014 1 2
3400 89000 4.33 91.6 0.4 na na 12 88.5 0.5 nil nil 0.14 nil nil 05/07/2014 1 2
6200 202000 5.87 69.1 0.5 na na 11.1 na 6 nil nil nil nil 03/12/2013 1 3
28800 628000 12.5 91.7 0.4 na na 8.1 111 na nil nil 1 nil nil 28/11/2014 1 2
14600 473000 4.26 76.8 0.5 22.3 73.4 11.1 85.5 na nil nil nil nil nil 28/02/2014 1 1
9400 225000 7.71 76.4 0.4 23.4 73.2 9.9 na nil nil nil nil nil 02/06/2014 1 1
18500 562000 6 92.3 0.9 24.1 70.2 10.7 101.3 na nil nil nil nil nil 28/11/2014 1 1
15600 222000 11.68 77.7 0.6 26.1 62.2 8.8 na 1 nil nil nil nil 19/09/2014 1 2
9700 653000 2.99 94.9 0.6 25.9 68.7 11 na nil nil nil nil nil 01/12/2014 1 1
3900 153000 na 84.8 0.6 24.2 73.2 na na na nil nil nil nil nil 07/05/2014 1 1
17000 414000 18.5 100 0.5 12.6 83.3 9.6 na nil 1 1 nil nil 26/12/2014 1 2
8000 206000 3.39 83.6 1.1 29.5 64.4 7.8 85.4 1.1 nil nil nil nil nil 03/02/2011 1 1
10900 260000 3.99 64.5 0.5 25.7 67.7 8.4 72.3 0.6 nil nil nil nil nil 22/08/2014 1 1
12600 356000 13.2 72.3 0.5 30 59 11.1 71.4 na nil nil 1 1 nil 03/06/2014 1 2
13300 171000 3.43 71.4 0.4 na na 8.9 na nil nil nil nil nil 07/02/2015 1 2
7700 195000 4.12 68.5 0.5 9.9 79.6 na na na nil nil nil nil nil 12/09/2014 1 2
17700 783000 8.12 89.6 0.5 22.7 73 10.5 na nil nil 0.5 nil nil 22/11/2014 1 2
9600 300000 5.49 88.7 0.6 24 71 10 na nil nil 1 nil nil 03/02/2015 1 2
13500 592000 9 83.1 0.4 18.6 77.8 6.8 na nil nil nil nil nil 01/08/2014 1 2
38400 445000 3.45 69.5 na 9 83.2 7.1 na 2 nil nil 1 nil 18/11/2014 1 2
9200 313000 6.2 69.6 0.5 30.6 53.4 8.9 na nil nil nil nil nil 18/03/2014 1 1
19900 289000 na 77.8 0.7 na na 12.5 0.6 nil nil 0.33 nil nil 22/01/2015 1 2
20400 390000 4.87 67.1 0.4 54 45.1 9 75.1 na nil nil nil nil nil 18/03/2014 2 1
19700 246000 9.36 91.8 0.4 16.9 79.1 na na na nil nil nil nil nil 31/10/2014 1 1
6100 126000 5.31 74.4 0.5 23 71 10.7 na nil nil 0.25 nil nil 12/12/2014 1 1
11600 180000 10.49 74.4 0.5 19.6 71.1 11.6 na na nil nil 1 nil nil 19/08/2014 1 2
10800 401000 na 75.2 0.9 8.6 82.8 na na na nil nil nil nil nil 15/09/2014 1 1
14700 362000 na 89.3 0.5 15.8 52.9 8.5 na nil nil nil nil 1 21/11/2014 1 2
13700 273000 4.32 74.2 0.7 na na na na na nil nil nil nil nil 11/04/2014 1 1
11900 356000 8.14 81.1 0.5 25.8 69.9 11.3 na nil nil nil nil nil 14/03/2014 1 1
7000 90000 7.58 96.1 0.9 23.1 74.5 11.6 na nil nil nil nil nil 10/05/2013 1 1
9000 176000 6.7 99.3 1.3 20.2 75.8 na na na na na nil nil nil 06/05/2014 2 3
14500 201000 6.38 59.5 na 6.1 81.3 7.8 0.5 nil nil nil nil nil 21/12/2012 1 1
14400 446000 7.44 94.3 na 17.4 77.2 na na na na nil nil nil nil 12/03/2014 1 1
12100 108000 5.95 70.1 na 25.4 65.4 9.7 na nil nil nil nil nil 02/09/2014 1 1
7400 236000 2.43 72.5 0.5 11.6 55.3 na na na 1 nil nil nil nil 05/09/2014 2 1
10600 526000 6.29 63.5 1 9.6 79.9 9.6 81.3 na nil nil 2 nil nil 17/09/2014 1 2
8200 146000 2.24 71.2 0.4 18.7 76.8 9.2 na nil nil nil nil nil 13/01/2015 1 1
5900 191000 2 106 0.6 22.8 72 na na na nil nil nil nil nil 26/11/2014 1 1
4500 102000 2.66 88.7 0.9 16.8 71.2 na na na na na nil nil nil 05/09/2014 1 2
39600 392000 na na 0.5 21.8 72 10 101.8 na nil nil nil nil nil 05/12/2014 2 1
5900 291000 na 68 0.4 12.7 82.2 na na na nil nil 2 nil nil 03/06/2014 2 2
14900 535000 13.8 85.6 0.5 30.7 63.3 9.1 82.9 na nil nil nil nil nil 22/07/2014 1 1
15900 478000 2.67 78.1 0.7 16.9 71.8 na na na nil nil 1 nil nil 23/08/2014 1 2
15400 141000 9.84 86.6 0.5 na na 8.8 na nil nil 1 nil nil 17/06/2014 1 2
5200 84000 7.71 81.3 0.7 22.4 52.4 na na na nil nil 1 nil nil 13/01/2015 1 2
9800 213000 3.8 70.8 0.5 na na 9 83.4 na nil nil nil nil nil 20/11/2014 1 1
10000 250000 6.24 89.1 0.4 na na 9.9 95.8 na nil nil nil nil nil 05/08/2014 1 1
9200 345000 4.4 64.6 0.5 na na 9.5 73.6 na 1 1 nil nil nil 30/10/2014 1 2
5400 253000 0.8 81.5 0.5 na na 9.2 80.7 na nil nil nil nil nil 10/02/2015 1 2
20600 511000 15.7 79.1 0.4 na na 8.9 na 1 nil nil nil nil 30/06/2014 1 2
10400 360000 7.74 90.8 0.6 11.4 83.8 8.7 na na nil nil nil nil nil 18/11/2014 1 1
13300 299000 9.7 101.7 0.5 24.1 69.4 11 na nil nil nil 1 nil 09/09/2014 1 2
8700 179000 18.54 92.7 0.3 9 77.1 10.1 109.4 0.5 1 nil nil nil nil 01/09/2014 1 1
7800 164000 4.99 72 0.79 28.8 62.4 10 75.9 na nil nil 0.5 nil nil 09/01/2015 1 2
15900 337000 10.14 75.2 0.39 22.7 72.8 na na na nil nil 0.5 nil nil 09/02/2015 1 2
6200 156000 5.65 70.4 na 16.2 78.2 na na na nil nil nil nil nil 21/08/2014 1 1
18500 375000 8.47 92.9 0.66 16.6 79.2 na na na na na 0.3 nil 1 17/10/2014 2 2
18400 660000 3.7 67.4 0.8 12.5 58.2 9.9 na 1 nil 0.5 nil nil 19/11/2014 1 2
10700 197000 4 57.7 0.5 19 69.9 11 82.9 0.7 nil nil nil nil nil 03/02/2015 1 1
14600 221000 3.89 63 0.5 29.6 58 8.8 75.5 0.5 nil nil nil nil nil 18/11/2014 1 1
5500 44000 1.92 67.6 0.82 12.2 76.3 na na na nil nil 1 nil nil 13/03/2014 1 2
30800 193000 7.7 94.1 0.7 na 64 9.2 102.3 0.7 nil nil nil nil nil 22/12/2014 1 1
10700 234000 8.6 88.9 0.6 13.2 82 9.8 135.9 0.9 nil nil nil nil nil 12/01/2015 1 1
8100 81000 10.45 90.3 1 7.9 86.6 11.2 107 na nil nil nil nil nil 04/08/2014 1 1
6700 114000 17.35 79.7 0.3 18.1 72.1 7.3 86.4 na 1 nil nil nil nil 04/11/2014 1 2
10800 145000 11.62 100.6 0.32 22.1 66.3 7.8 na nil nil nil nil nil 02/12/2014 1 na
8500 196000 5.5 91 0.4 21.6 61.2 10.1 na nil nil nil nil nil 08/04/2014 1 1
11800 448000 10 92.4 0.5 16 77.8 8.9 108.8 na nil nil nil nil nil 06/01/2015 2 2
7500 153000 1.82 76 0.9 17.7 76.8 na na na nil nil nil nil nil 05/01/2015 1 na
8700 312000 0.87 86.7 0.5 na na 11.6 97.6 na nil nil nil nil nil 22/12/2014 1 1
17100 349000 5.37 64.1 0.5 23 64.5 9.2 67 na nil nil nil nil nil 28/11/2014 1 2
6800 163000 0.94 82.1 0.43 na na 10 88.3 0.3 1 nil nil nil nil 09/01/2015 1 1
9900 175000 7.5 62.7 0.4 na na 8.5 73.2 na nil nil nil nil nil 17/06/2014 1 1
9100 281000 6.7 77.9 0.5 33.3 61 9.3 87.1 na nil nil nil nil nil 25/03/2014 1 1
15800 297000 5.9 63.4 0.2 na na 9.4 72.8 na 1 nil nil nil nil 08/12/2014 1 1
14600 268000 3.12 74.5 0.4 na na 10.6 93.6 na nil nil nil nil nil 20/02/2015 1 1
5000 17000 8.15 79 0.8 16.1 38.2 7.7 86.5 na 8 1 1 nil nil 09/05/2014 1 3
3600 96000 12.6 73.6 0.5 na na 5.5 0.7 6 nil nil nil nil 06/02/2015 1 1
10400 206000 12.2 82.3 0.4 25.7 74 na na na nil nil nil nil nil 29/01/2015 1 1
14700 271000 10.6 75.4 0.57 14 80.5 9.2 80.9 na 3 nil nil nil nil 26/12/2014 1 2
8700 126000 5.12 93.8 0.7 21 74.8 na na na nil nil nil nil nil 03/02/2015 1 1
9900 202000 7.99 99.2 0.8 21.3 71.9 9.4 109.7 na nil nil nil nil nil 26/06/2014 1 1
9200 120000 3.58 74.2 0.86 20.5 72.1 na na na nil 2 2 nil nil 17/05/2014 1 2
16000 302000 10.77 92.1 0.3 24.5 71.7 10.4 96.5 na nil nil nil nil nil 27/10/2014 1 1
22700 160000 18.3 88.9 0.75 25.3 70.8 9.8 89.4 na nil nil nil nil nil 22/12/2014 1 1
6900 108000 13.95 66.8 0.4 24.2 70.5 8.9 na nil nil nil nil nil 13/10/2014 1 NA
17000 352000 6.28 88.8 0.6 19.5 73.8 10.5 na nil nil nil nil nil 09/05/2014 1 1
22100 332000 3.22 71.8 0.5 36.6 55.6 11.6 83.5 na nil nil nil nil nil 30/12/2014 1 1
13200 397000 9.19 74.2 0.38 17 77.8 6.5 87 na 1 nil nil nil nil 31/03/2014 1 2
7800 107000 3.3 73.5 0.7 19.9 69.9 10.4 72.8 na nil 1 0.5 nil nil 28/07/2014 1 2
9300 278000 2.6 69.5 0.7 18 75.7 10.1 73 0.3 nil nil nil nil nil 12/08/2014 1 1
6000 117000 11.53 88.9 0.3 9.5 51 10.8 108.8 0.3 1 nil nil nil nil 02/12/2014 1 1
7300 82000 2.17 86.3 0.5 41.9 27.8 na na na 1 nil nil nil nil 08/07/2014 1 NA
10400 221000 7.98 85.9 0.8 7 86.4 8.9 117.5 na nil nil nil nil nil 08/09/2014 2 1
11500 392000 11.3 104.7 0.8 23.4 71.2 7.7 118 na 1 nil nil nil nil 21/10/2014 2 2
16500 395000 11.89 87.4 0.4 22 73 na na na nil nil nil nil nil 15/07/2014 1 1
7800 191000 6.38 81.1 0.76 25.7 69.3 na na na na na nil nil nil 12/08/2014 1 1
13900 192000 5.39 82.7 0.8 22.2 68.7 11.2 75.4 na nil nil nil nil nil 17/02/2015 1 1
10800 181000 4.3 72 0.6 10.4 83.7 10.5 76.5 na nil nil 1 nil nil 18/07/2014 1 2
8500 124000 4.7 63.2 0.5 19.5 73.1 11.3 81.9 na nil nil nil nil nil 16/01/2015 1 1
5400 113000 13.4 95.3 na 21.9 73.4 na na na nil nil nil nil nil 02/12/2014 1 1
6700 214000 2.68 75.5 na 23 70.4 12.7 83.5 na nil nil nil nil nil 23/12/2014 1 1
17000 538000 6.5 77.3 0.5 19.5 73 9.7 84.5 0.3 nil nil nil nil nil 09/09/2014 1 1
8000 279000 4.3 75.6 0.4 20.1 71.1 10.6 81.1 0.4 nil nil nil nil nil 09/09/2014 1 1
13700 378000 7 78.9 0.9 14.9 80.2 na na na nil 2 2 nil nil 26/09/2014 2 2
18700 213000 na 88 0.5 7.6 87.3 10.6 na nil nil nil nil nil 08/09/2014 1 1
11300 355000 5.13 101.5 0.5 24.6 70.1 na na na nil nil nil nil nil 12/08/2014 1 1
10100 279000 2.79 67.6 0.6 16.9 76.7 na na na nil nil nil nil nil 11/08/2014 1 1
18200 407000 8.8 87.2 na 25 69.7 na na na nil 1 nil nil nil 10/06/2014 1 1
10200 357000 5 92.3 0.5 19.1 71.7 10.1 111.4 na nil nil nil nil nil 17/06/2014 1 1
13500 309000 6.2 76.3 0.5 21 74.1 9.4 na nil nil nil nil nil 10/06/2014 1 1
12100 426000 6.15 79.3 0.2 16.8 77.9 9.5 na nil 2 2 nil nil 09/09/2014 2 2
10200 161000 7.32 75.1 0.5 12.1 82.6 8.7 na nil nil nil nil nil 09/09/2014 1 1
6700 77000 5.9 98.7 na na na 12.1 118.1 na nil nil nil nil nil 12/12/2014 1 1
15200 228000 6.2 66.1 0.5 na na 7.7 67.4 na nil nil nil nil nil 16/12/2014 1 1
6200 235000 3.3 69.2 0.6 16.8 70.2 na na na nil nil nil nil nil 23/05/2014 1 1
10400 513000 3.3 67.5 0.5 11.4 43.4 na na na nil nil nil nil nil 10/06/2014 1 1
10400 257000 4.7 68 0.8 na na na na na nil nil nil nil nil 30/09/2014 1 1
13000 332000 5.1 85.7 0.3 20.2 75.4 na na na nil nil nil nil nil 10/10/2014 1 1
9200 101000 18.8 89.5 0.4 na na 8.7 80.3 0.5 nil nil 1 nil nil 08/11/2011 2 2
14200 396000 4.4 na 0.4 17.6 69 9.8 83.3 na nil nil nil nil nil 28/06/2011 2 2
10500 166000 8.3 78.5 0.7 na na 11 98 na nil nil 1 nil nil 09/07/2010 2 2
6500 118000 8.4 90.1 na 17.7 76.8 na na na nil nil nil nil nil 11/07/2009 1 1
7300 154000 13.16 105 0.5 21.8 73.4 8.6 na nil nil nil nil nil 06/01/2015 2 1
15900 416000 7.4 83.2 na 17.8 77.8 10 na nil nil 1 nil nil 07/09/2009 1 2
20100 163000 23.6 108.2 0.4 18.2 68.1 na na na nil nil nil nil nil 26/07/2011 1 1
15300 302000 7.7 75.1 0.6 13.4 81 na na na nil 1 1 nil nil 08/12/2008 2 2
5400 132000 4.12 87.7 na 33.3 65.2 9.6 95.2 na nil nil 1 nil nil 01/12/2008 1 2
11200 289000 2.3 82.3 0.4 12 na 7.4 87.8 na nil nil nil nil nil 08/10/2008 1 1
5600 175000 2.5 70.4 0.8 25.3 64.4 na na na nil 1 1 nil nil 05/07/2013 1 NA
15000 374000 4.2 86 0.7 17 76.9 na na na nil 1 0.5 nil nil 04/05/2012 2 2
17000 365000 10.3 89.9 0.4 28.1 70 10 na nil nil nil nil nil 26/08/2008 1 1
11500 255000 2 84.9 0.5 19.4 64.4 9.8 97.9 na nil nil nil nil nil 01/04/2011 1 1
12000 405000 5.2 98.6 0.7 20.4 73.7 10.2 0.8 nil nil nil nil nil 13/10/2011 1 1
15600 400000 na 94.1 0.6 17.3 77.2 8.5 na nil nil nil nil nil 26/02/2011 1 1
8000 323000 6.1 65.7 0.4 na na na na na nil nil nil nil nil 24/12/2013 1 1
18200 503000 12.9 95.1 0.7 18 80 7.6 na nil nil nil nil nil 15/10/2011 2 2
28600 499000 7.4 79.3 0.5 na na 10.6 102.5 na nil nil nil 1 nil 05/03/2013 1 2
13800 136000 4.86 65.8 0.5 na na 9.4 76.3 na 2 nil nil nil nil 23/04/2012 1 2
9800 114000 4 67.1 0.6 na na na na na nil nil nil nil nil 22/02/2013 1 NA
6200 120000 5.7 63.8 0.5 na na 8.3 68.4 na nil nil nil nil nil 29/03/2011 1 2
4900 189000 6.9 87.1 0.8 35 62 na na na nil nil nil nil nil 19/02/2010 1 1
14300 329000 5.5 66.5 0.5 16 75 10.5 67.7 0.5 nil nil nil nil nil 16/07/2012 1 1
10100 212000 6.3 72.7 0.7 na na 12.8 0.8 nil nil nil nil nil 15/03/2013 1 1
8700 318000 5.3 94.8 0.7 19.9 75.8 na na na nil nil nil nil nil 20/10/2011 1 1
12600 296000 11.5 89.9 0.6 12 83.7 7 na nil nil nil nil nil 23/09/2013 1 1
8000 253000 3.9 85.3 0.7 24.4 72.2 na na na nil nil nil nil nil 22/06/2010 1 1
8100 70000 7.1 67.7 0.5 19 72.2 na na na nil nil 1 nil nil 26/06/2013 2 2
13900 409000 5.6 91.5 0.5 27 66 na na 0.6 nil nil nil nil nil 11/08/2011 2 1
14400 154000 8.2 97.2 na na na na na na nil nil nil nil nil 31/07/2010 1 1
8100 362000 0.68 71.2 0.5 na na 9.2 69.3 na 1 nil nil nil nil 11/09/2009 2 1
8400 163000 4.6 65 na 35.5 55.6 8.4 65.8 na nil nil nil nil nil 24/01/2009 1 NA
15600 276000 15.13 74.6 0.5 na na 7.9 78.3 na nil nil nil nil nil 21/10/2009 1 1
7300 116000 5.5 93.4 0.7 25.1 70.7 11 0.7 nil nil nil nil nil 05/10/2010 1 1
20400 289000 5.34 66.1 0.5 11.3 77.5 na na na nil nil nil nil nil 07/05/2013 2 1
9400 159000 3.94 90.8 0.6 18.2 75.2 na na na nil 1 1 nil nil 17/11/2010 1 2
13900 357000 10.15 93.5 0.6 12.7 80.6 na na na nil nil 1 nil nil 30/05/2011 2 2
6000 54000 2.71 75.1 0.6 21.6 69.7 na na na n nil nil nil nil 10/05/2011 2 1
15300 413000 3.9 95.5 0.7 18 55 na na na nil nil nil nil 1 10/02/2012 2 2
7400 240000 2.89 79.6 0.7 22 73.4 9.9 83.7 0.7 nil nil nil nil nil 14/02/2011 1 1
10000 3449000 5.9 62.4 0.4 11.6 77 na na na 1 nil nil nil nil 19/06/2012 2 2
13400 319000 3.06 75.9 0.7 10.9 82.9 na na na nil nil 1 nil nil 27/02/2015 2 2
5200 275000 7.51 84.6 0.7 27.8 68 10.4 88.6 na nil nil nil nil nil 09/02/2013 1 1
12600 287000 5.63 73.4 0.7 8.7 78 na na na nil nil nil nil nil 08/06/2012 2 1
18600 441000 8.5 103.3 0.5 18.1 76.9 9.9 109.1 na nil nil nil nil nil 14/11/2012 1 1
5200 78000 4.5 96.7 0.9 24.7 71.9 12.5 101 na nil nil nil nil nil 02/03/2012 1 1
15100 212000 7.2 80.6 0.5 11.2 75 9.6 91.1 na 2 1 1 nil nil 03/05/2011 1 2
6400 267000 na 0.7 na na na na na nil nil nil nil nil 08/12/2011 1 1
10200 132000 4.43 73.1 0.7 19.4 70.4 na na na 1 1 0.5 nil nil 01/08/2013 1 2
15800 557000 6.1 80 0.8 7.2 80.3 9.5 70.7 0.7 nil nil nil nil nil 24/09/2013 1 1
12100 56400 7.4 0.5 25.2 73.1 na na na nil nil 1 nil nil 10/04/2012 2 NA
8100 117000 5.06 66.6 0.8 19.9 70.6 na na na nil nil nil 1 nil 19/12/2013 1 2
10000 376000 3.91 99.6 0.5 18 71.4 na na na nil nil nil nil nil 01/09/2011 1 1
26000 373000 5.85 71.1 0.3 16.7 71.7 6.8 68.8 0.4 1 nil nil nil nil 19/06/2012 1 2
6500 73000 5.63 83.9 0.7 18.3 74.5 12.2 na nil 1 nil nil nil 31/12/2013 1 1
7500 310000 5.58 79.6 0.6 20.1 75.4 na na na nil nil nil nil nil 17/01/2014 2 2
13800 183000 23.48 92.6 0.6 26.3 70.4 8.9 95.1 na nil nil nil nil nil 06/08/2013 1 1
11500 529000 8.61 84.6 0.5 21.7 73.9 9.3 0.3 nil nil nil nil nil 26/12/2013 1 1
11800 99000 7.21 69.3 0.5 13.6 74 11.3 0.7 nil nil nil nil nil 20/08/2013 1 1
16900 181000 5.13 62.3 0.6 25.9 72.4 9.9 88.4 na nil nil nil nil nil 22/07/2013 1 1
10900 243000 3.59 80.2 0.4 23 64 na na na nil nil nil nil nil 30/04/2012 1 1
8800 112000 3.2 74.2 0.7 19.7 77.2 na na na nil 1 1 nil nil 04/02/2014 2 2
4900 56000 8.15 70.9 0.8 16.6 71 8.3 na 2 nil nil nil nil 28/03/2012 1 2
5700 155000 8.47 75.2 0.5 na na 7.4 82.5 na 4 nil nil nil nil 15/01/2013 2 3
3900 152000 5.75 86.4 0.5 20.4 71.1 9.4 97 na nil 1 nil nil nil 13/11/2012 2 1
16300 349000 1.87 84.7 0.5 na na 10.7 92.4 na nil nil nil nil nil 08/06/2012 1 1
2100 95000 4.26 78.8 0.6 na na na na na nil nil nil nil nil 28/03/2013 1 1
10100 317000 6.8 59.9 0.4 30.1 64.6 9.6 0.4 nil nil nil nil nil 25/02/2013 1 1
4400 113000 5.2 69.1 0.5 21 72.2 7.7 77.6 na nil nil nil nil nil 21/09/2013 1 1
8900 141000 4.8 63.7 1.1 14.7 68.4 9.5 86.3 na nil nil nil nil nil 17/06/2013 1 1
14000 346000 na 93.2 0.8 9.7 82.7 9.9 na nil nil nil nil nil 26/12/2013 1 1
4500 65000 5.88 78 0.6 23.5 63.5 11.9 na nil nil nil nil nil 03/12/2013 1 1
11600 224000 6.4 94.6 1.01 14.8 79.6 11.5 145.8 na nil nil nil nil nil 18/12/2013 1 1
4800 11000 5.6 82.2 1 na na na na na 4 nil 1 nil nil 19/04/2013 1 2
7800 12900 3.3 71.5 0.7 na na na na na nil nil nil nil nil 13/02/2013 1 1
12400 120000 2.4 64.5 0.59 15.6 46 na na na nil nil nil nil nil 12/11/2013 1 1
6000 175000 2.9 74.2 0.4 28 61 10.3 77.3 na nil nil nil nil nil 26/03/2013 1 1
8500 83000 9.3 88.8 0.89 na na 11.5 na 0.8 nil nil nil nil nil 03/10/2013 1 1
5600 99000 8.8 73.7 0.6 na na 9.3 80.2 na nil nil nil nil nil 24/09/2013 1 1
6200 219000 8 86.4 0.4 na na 12.2 na na nil nil nil nil nil 10/10/2013 1 1
9900 215000 0.98 76.8 0.5 na na 9.9 83.6 na nil nil nil nil nil 10/10/2013 1 1
11700 236000 6.2 71.8 0.6 na na 9.2 66.9 na nil nil 1 nil nil 01/10/2013 1 2
7000 211000 13.3 91.2 0.25 21.9 76.5 8.5 92.4 na nil nil nil nil nil 30/01/2014 1 1
17900 158000 9.2 86.3 0.5 na na na na na nil nil nil nil nil 24/10/2013 1 1
7500 297000 6.2 79.2 0.4 29.9 61.5 10.1 na na nil nil nil nil nil 17/06/2014 1 2
10100 142000 23.76 72.1 na 24.8 65.6 8.7 na na nil nil 1 nil nil 09/06/2015 2 2
15300 398000 5.1 86.5 0.8 9.9 65 11.3 96.6 0.7 nil 1 1 nil nil 18/07/2014 2 2
8900 193000 5.5 85.5 0.7 26.4 69.8 11.5 92.2 na nil 1 1 nil nil 24/06/2014 1 2
17400 118000 18.49 85.7 0.5 na na na na na 1 nil 1 nil nil 20/10/2014 1 2
9100 333000 3.37 73.7 0.5 29.2 58.4 na na na nil nil 1 nil nil 15/12/2014 2 2
14000 na na na na 7.5 66.1 na na na nil nil 1 nil nil 23/02/2009 2 2
15600 523000 11.8 96.7 0.5 na na 10.9 114.6 na nil 1 1 nil nil 26/08/2011 1 2
13200 270000 4 85.5 na 27.3 68 na na na nil nil 0.25 nil nil 06/12/2011 1 2
4800 82000 3.78 87.2 0.6 30.7 62.2 9.4 78.4 0.6 nil nil nil nil nil 12/06/2012 2 1
13100 238000 9.2 83.5 0.4 12.2 81.8 8.4 88.4 na nil 1 1 nil nil 14/04/2008 1 2
8000 233000 4.8 68.4 0.6 12.1 78.8 9.3 na 0.6 nil nil nil nil nil 08/03/2007 1 1
10100 148000 12.68 87.7 0.4 na na 8.5 85.8 na 2 nil nil nil nil 19/05/2010 1 3
